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ABSTRACT  
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder caused by a 
polyglutamine expansion within the N-terminal region of huntingtin protein. The mutation is 
likely to confer a novel toxic property to the protein, which initiates a disease cascade that 
broaden with time and culminates in neuronal loss.  
 
In the present study we have investigated the contribution to the pathogenesis of HD of Pin1 
and Rrs1, two proteins already implicated in neurodegeneration.   
 
The identification of cellular factors promoting mutant huntingtin degradation is of great 
interest in HD pathology as they can lower the level of toxic protein. In this context, we have 
considered the prolyl-isomerase Pin1 as a good candidate for its role in modulating aggregate 
formation in other neurodegenerative disorders including Alzheimer’s and Parkinson’s 
diseases. In the present work we show that in cell culture Pin1 overexpression reduces the 
formation of mutant huntingtin intracellular inclusions. In agreement with this observation we 
demonstrate that Pin1 decreases huntingtin half-life by promoting the activity of the ubiquitin 
proteasome system. Additional studies are currently underway to unveil the role of Pin1 in 
modulating huntingtin aggregation in vivo using the double HdhQ111:Pin1-/- mouse model we 
have generated.  
The conformational change catalyzed by Pin1 on its substrates regulates a number of cellular 
processes, which include, among others, the control of gene transcription. We have previously 
shown that Pin1 is a new huntingtin interactor (unpublished results). In the present work we 
explore the interplay between Pin1 and mutant huntingtin in deregulating the transcriptional 
programs in neurons. Gene expression profiling has been carried out on STHdh striatal cells 
upon Pin1 silencing and on striatum of HdhQ111/Pin1-/-  mice. We report here preliminary lists 
of genes with change in gene expression in absence of Pin1.  
 
The second study of this thesis work is directed to explore the role in HD of Rrs1 (Regulator 
of ribosome synthesis), a gene already implicated in the early phase of the disease process. 
Rrs1 is an evolutionary conserved protein characterized so far exclusively in Saccharomyces 
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cerevisiae where it participates in ribosome biogenesis. Here we present the first description of 
Rrs1 protein in mammalian cells, where it localizes both in the nucleolus and in the ER. 
Furthermore, we provide evidence that in striatal cell lines Rrs1 mRNA is up-regulated upon 
induction of ER stress. In addition we report that mutant huntingtin induces ER stress in the 
striatum of HdhQ111 knock-in mice at a very young age, when Rrs1 mRNA levels were found 
increased. 
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CHAPTER 1: INTRODUCTION 
1.1 Huntington’s Disease 
1.1.1 Brief history of the disease 
“There are three marked peculiarities in this disease: 1. Its hereditary nature; 2. A tendency 
to insanity and suicide; 3. Its manifesting itself as a grave disease only in adult life”.  
With these words George Huntington in 1872 describes in his paper "On Chorea" the 
distinguishing features and the hereditary nature of this devastating neurodegenerative 
disorder, named after him Huntington's Disease (HD). 
In 1981 the U.S.-Venezuela Huntington’s Disease Collaborative Research Project was 
founded and a team of scientists joined together with the aim to identify the chromosomal 
region and the gene responsible for HD. Two large families, one from Venezuela, one from 
the United States were studied and in 1983 the gene linked to the disease was mapped on 
chromosome 4 (Gusella, 1983).  
Ten years later, in 1993, the HD gene was finally isolated (HDCRG 1993). The mutation 
responsible for the disease was identified as a polymorphic trinucleotide (CAG) repeat in the 
5’ region of a novel gene that expands beyond the normal range in the disease chromosomes. 
Unfortunately more than fifteen years after the isolation of the HD gene, a treatment for this 
disorder, affecting in Europe 5-10 individuals out of 100,000, is still not available.  
1.1.2 Clinical manifestation of HD 
Although HD is characterized by multiple symptoms, a clinical diagnosis is made following 
the unequivocal presence of the movement disorder associated with HD in the context of a 
family history and/or a positive genetic test result (Williams, 2007).  
Psychiatric symptoms with changes in cognition and behavior precede the onset of motor 
disturbances by a decade or more. Early psychiatric disturbances include mood and 
personality changes, apathy and depression (Paulsen, 2005), alterations in memory (Lemiere, 
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2004), learning and planning abnormalities (Rosenberg, 1995) and sleep disturbances 
(Morton, 2005). 
As the disease progresses, affected individuals develop overt choreiform movements of head, 
neck, arms and legs, which increase with time, including facial grimacing and twisting and 
jerking of the trunk and limbs (Bachoud-Levi, 2001). Weight loss, which also characterizes 
the disease, may be due to dysphagia as well as degeneration of hypothalamic orexin/positive 
neurons (Petersen, 2005). 
The clinical manifestation of HD typically begin in midlife with a mean age at onset of about 
40 years, but its symptoms can also occur as early as 2 years of age and as late as 80 to 90 
years. The juvenile-onset individuals have quite a different clinical description compared to 
the typical adult-onset cases with muscular rigidity, bradykinesia, tremor and the absence of 
abrupt movements and chorea (Hayden, 1981; Squitieri, 2000). The age at onset is closely 
correlated with the extent of the mutation as it will be discussed in chapter 1.1.5. 
The most common causes of death in HD are cardiovascular disease and pneumonia following 
general debility from incessant choreic movements, injuries related to serious falls, poor 
nutrition and infection. Choking, secondary to aspiration of food, and suicide (Di Maio, 1993) 
are also relatively common causes of death. 
1.1.3 Neuropathology of the disease 
The clinical manifestations are associated with a distinctive neuropathology. A specific and 
gradual loss of medium spiny projecting neurons (MSN) in the striatum, with some associated 
degeneration of the cerebral cortex is observed. In the more severe young onset cases the 
neuronal pathology extends to other brain areas including thalamus and cerebellum. 
Examination of coronal section reveals atrophy of the striatum in postmortem brains of HD 
patients (Fig. 1). The neurodegeneration of the striatum occurs first in the caudate nucleus, 
then in the putamen.  
 
Figure 1:  Coronal section passing through the nucleus accumbens of 
the left cerebral hemisphere of a normal individual, compared 
to the right cerebral hemisphere of an HD patient postmortem 
brain (Adapted from Vonsattel and DiFiglia, 1998). 
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At death, about 10 to 20 years after the onset of clinical manifestation, the basal ganglia is 
ravaged and overall brain weight is reduced by a third (Vonsattel and DiFiglia, 1998). 
Although the most obvious and striking neuropathology of HD is the dramatic loss of medium 
spiny neurons, thorough examination shows that other brain regions are affected in HD. 
Cortical cell loss is often reported even if less severe, mostly affecting the large neurons in 
layer V and VI, which project to the striatum (Hedreen, 1991). 
Hypothalamic atrophy and cell death also occur (Petersen and Bjorkqvist, 2006). 
Neuropathological studies of HD patients have demonstrated up to 90% neuronal loss in the 
lateral hypothalamus (Kremer, 1990; Kremer, 1991) and in particular loss of neurons 
expressing the neuropeptide orexin (Petersen, 2005). 
In addition, in post mortem studies a significant microglia activation has been described in the 
areas of neuronal loss, including the striatum, globus pallidus and frontal cortex (Sapp, 2001). 
Extra-neural abnormalities reported in literature include increased diabetes (Podolsky, 1972) 
and peripheral muscle weakness (Homberg and Huttunen, 1994), although most of these data 
require further epidemiological study (Valenza, 2005). Increased stress-induced apoptotic 
death in lymphocytes (Sawa, 1999), muscle pathology (Strand, 2005) and endocrine changes 
have been also described (Petersen and Bjorkqvist, 2006). 
1.1.4 Motor circuits in Huntington’s Disease 
The striatum is the main input compartment of a system called basal ganglia (Fig. 2), which 
are a collection of subcortical nuclei involved in the control of movement.  
Figure 2:  Scheme of a coronal section of the 
human brain, showing the position of the 
basal ganglia and their different sub-
nuclei. The basal ganglia are composed 
of four principal nuclei: the striatum, the 
globus pallidus (GP) consisting of 
external and internal segments (GPi and 
GPe), the substantia nigra (SN) 
consisting of pars compacta and 
reticulata (SNc and SNr), and the 
subthalamic nucleus (STN) (Adapted 
from Neuroscience, 2001 by Sinauer 
Associates). 
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The striatum receives massive glutamatergic and dopaminergic innervations from all regions 
of the cerebral cortex as well as specific thalamic nuclei. The flow of information returns to 
the cortex through the thalamus, which is the major output structure. 
The primary motor dysfunctions in HD are due to the degeneration of the medium-sized spiny 
neurons (MSNs). The MSNs are projection neurons and represent more than 90% of the 
striatal cell population. Although all MSNs are GABAergic, they differ in a number of 
properties including the expression of dopamine and acetylcholine receptor subtypes, peptide 
content and projection targets.  
A classical model describes two major neuronal motor pathways, referred to as direct and 
indirect pathways, which act in opposition, and correctly predicts the motor impairment in 
Huntington’s disease (Albin, 1989). GABAergic neurons at the origin of the direct pathway 
mainly express dopamine D1 and muscarinic M4 receptors, substance P, and project to the 
GPi. On the other hand, GABAergic neurons of the indirect pathway mainly express 
dopamine D2 receptors and enkephalin, and project to the GPe (Reiner, 1988; Albin, 1991; 
Richfield, 1995; Sapp, 1995). Early Huntington’s disease is characterized by loss of the 
projection neurons of the indirect pathway which causes an imbalance in favor of the direct 
pathway. Movements are therefore initiated, but can neither be controlled nor stopped (Albin, 
1989). At later stages, the general loss of the MSNs, including those projecting through the 
direct pathway, induces a drastic motor dysfunction leading to bradykinesia. 
1.1.5 Etiology of the disease 
Huntington's disease was the first autosomal dominant disorder in which the technique of 
“reverse genetics” was successfully applied. The human HD gene (IT15), located to 
chromosome 4p16.3, contains 67 exons spanning more than 200 kb and encodes for a ~350 
kDa protein named huntingtin (HDRCG, 1993). The 5' end of the gene contains a highly 
polymorphic stretch of repeated CAG trinucleotides ranging from 6 to 35 repeats. By contrast, 
HD mutant alleles that produce the full disease phenotype have 36 to more than 250 CAG 
repeats (Gusella and MacDonald, 2002).  
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The CAG repeats on HD chromosomes are remarkably unstable through germline 
transmission. Contractions and expansions are equally likely with maternal transmission, but 
expansions are more common than contractions with paternal transmission (Wheeler, 2007). 
The relationship between the size of the CAG repeat and the age at onset of neurological 
symptoms has been examined in numerous data sets showing a strong inverse correlation. HD 
is typically a mid-life pathology associated with CAG allele lengths of 40 to 50 units. Disease 
alleles with CAG expansion in the 35 to 40 unit range may show very late onset or, in some 
cases, may be nonpenetrant. By contrast, individuals with more than 60 CAG units typically 
show onset of HD in their juvenile years.  
CAG repeat length however account for about 70% of the variation in age at onset being the 
remaining variation attributable to environmental factors or to genes other than the HD gene 
(Li, 2006; Wexler, 2004). Among the potential modifier genes, the serum and glucocorticoid 
regulated kinase (sgk) and the metabotropic glutamate receptor 1 (mGlur1) are of particular 
interest (Li, 2006). 
1.1.6 Triplet repeat disorders 
Expanded trinucleotide repeat mutations have been associated with a growing number of 
inherited human disorders. This class of mutations was first identified in 1991 as the cause of 
spinal and bulbar muscular atrophy (SBMA) and fragile X syndrome (FRAXA) (La Spada, 
1991). Since then, triplet repeat expansions have been found to be the causative mechanisms 
in 14 other neurodegenerative disorders including HD. Unifying features among these 
diseases include the unstable behavior of the triplet repeat during germline transmission when 
the length of the repeat exceeds a critical value (Orr and Zoghbi, 2007).  
Trinucleotide repeat diseases can be categorized into two subclasses based on the location of 
the triplet repeats: diseases involving repeats within coding sequences (exonic) and diseases 
involving noncoding repeats (untranslated sequences).  
Huntington’s disease belongs to the first group, which includes nine disorders caused by 
expansion of the same repeated codon (CAG) into the coding region of different genes (Tab. 
1). Since the expansion of the CAG repeats encodes for a polyglutamine tract, these diseases 
are commonly referred to as polyglutamine (or polyQ) disorders. Interestingly, all polyQ 
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diseases are characterized by the presence of insoluble ubiquitinated aggregates and by 
degeneration of specific brain regions, despite the ubiquitous expression of the corresponding 
proteins. 
The second group, non-PolyQ diseases, does not share any specific symptoms and include: 
Fragile X syndrome, Fragile XE mental retardation, Friedreich's ataxia, Myotonic dystrophy, 
SCA8 (Spinocerebellar ataxia Type 8), and SCA12. 
 
 
Tab. 1:  Polyglutamine disorders (Orr and Zoghbi, 2007). 
1.2 Huntingtin protein 
Human huntingtin (NP_002102) contains 3144 amino acids with a molecular weight of ~350 
kDa and very little homology to any other known protein. The polyQ region, encoded by the 
CAG stretch, is immediately downstream amino acid 17 of huntingtin and upstream to a 
polyproline (polyP) rich region. Across the entire protein have been identified 36 HEAT-like 
repeats (Huntingtin, Elongation factor 3, subunit A of protein phosphatase 2A, TOR1) 
(Takano and Gusella, 2002), which are sequences of about 40 amino acids that form 
hydrophobic  helices and assemble into an elongated superhelix (Andrade and Bork, 1995). 
The function of HEAT repeats is still unclear, although they have been found predominantly 
in proteins involved in intracellular trafficking and chromosomal segregation. Analogous to 
other HEAT repeat proteins, huntingtin may act as a scaffold molecule facilitating the 
formation of a variety of complexes (Takano and Gusella, 2002). Huntingtin is expressed 
ubiquitously in humans with the highest levels in brain and testis. In the brain, high levels are 
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found in the cerebellar cortex, neocortex, striatum and hippocampus (Schmitt, 1995). In most 
cells huntingtin is essentially a cytoplasmic protein associated with various organelles 
including mitochondria, endoplasmic reticulum and Golgi complex (DiFiglia, 1995; Trottier, 
1995), however a fraction is also found in the nucleus (Wheeler, 2000; Tao and Tartakoff, 
2001; Kegel, 2002).  
Huntingtin is an essential protein that is required for normal embryogenesis, as knockout mice 
die at an early developmental stage (E 7.5) (Duyao, 1995; Nasir, 1995). Conditional 
knockouts mouse models have demonstrated that huntingtin is also essential at postnatal 
stages, as the inactivation of the gene in brain and testis leads to degeneration of these two 
tissues (Dragatsis, 2000). Mice homozygous for reduced levels of huntingtin displayed 
characteristic aberrant brain development and perinatal lethality, indicating a critical function 
for Hdh in neurogenesis (White, 1997). In Drosophila, the reduction of huntingtin expression 
causes axonal transport defects in larval nerves and neurodegeneration in adult eyes 
(Gunawardena, 2003). These studies indicate that huntingtin is required for cell survival and 
suggest that a loss of function of the protein might induce neurodegeneration (see chapter 
1.2.3).  
1.2.1 Huntingtin, a player of many games 
Despite substantial effort has been spent to understanding huntingtin function, a complete 
picture of its normal activities is not yet available. This is mainly due to the large size of the 
protein that makes isolation and analysis difficult, to the lack of obvious homology with other 
proteins and to its ubiquitous localization and promiscuous interactions with more than 200 
partners identified to date (Harjes and Wanker, 2003; Li and Li, 2004; Borrell-Pages, 2006; 
Kaltenback, 2007).  
Most of the proteins have been found to interact with the N-terminal region of huntingtin and, 
in several cases, the strength of the interactions has been shown to be sensitive to the length of 
the polyQ tract (Tab. 2) (Harjes and Wanker, 2003; Li and Li, 2004). 
The different biological roles of the interactors have implicated huntingtin in processes as 
diverse as transcriptional regulation, RNA splicing, signal transduction, intracellular 
trafficking, cytoskeletal organization and protein folding and turnover (Li and Li, 2004). 
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At the same time, other huntingtin partners, involved in post-translational processes, target 
huntingtin to different subcellular compartments, supporting the hypothesis of a scaffold 
protein involved in dynamic protein-protein interactions.  
 
Tab. 2:  Proteins that interact with huntingtin. Arrows indicate whether these interactions are increased or 
decreased by the polyQ expansion. NT, N terminal; CT, C terminal (Borrell-Pages et al., 2006b). 
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To date, huntingtin protein has been described to undergo post-translational modifications that 
include palmitoylation, ubiquitination, SUMOylation and phosphorylation.  
Palmitoylation at cysteine 214 by huntingtin interacting protein 14 (HIP14) is a critical 
modification for its normal trafficking to the Golgi (Yanai, 2006). Ubiquitination and 
SUMOylation occur both at the same N-terminal residues (K6, K9, and K15), but the former 
targets huntingtin to proteasomal degradation, whereas the latter stabilizes the protein and 
promotes its capacity to repress transcription (Steffan, 2004).  
Phosphorylation of huntingtin at serines 421, 434, 1181 and 1201 has been reported to 
promote cell survival.  
Huntingtin is phosphorylated at serine 421 by the pro-survival signaling kinase Akt (Humbert, 
2002) and by the serum and glucocorticoid-induced kinase SGK (Rangone, 2004). Huntingtin 
is also phosphorylated at serine 434, 1181 and 1201 by Cdk5, a member of the 
serine/threonine cyclin-dependent kinase (Cdk) family (Luo, 2005). 
Both Akt and CdK5 phosphorylation of huntingtin have been shown to be protective against 
polyQ-expansion-induced toxicity (Humbert, 2002; Luo, 2005; Anne, 2007). 
Other huntingtin phosphorylation sites at serine 533-5-6, 2076, 2653 and 2657 have been 
identified by mass spectrometry (Schilling, 2006) but their role in mediating huntingtin 
function/dysfunction is still unknown. 
It is noteworthy that huntingtin phosphorylation at position 434, 1181, 1201, 2076, 2653 and 
2657 occurs at serine (or threonine) residues followed by a proline (Ser-Pro or Thr-Pro). This 
kind of post-translational modification is indicated as proline-directed phosphorylation. These 
residues, when phosphorylated, are potential consensus binding sites for the peptidyl-prolyl 
isomerase Pin1 (see chapter 1.6). 
1.2.2 Mutant huntingtin and HD pathogenesis 
Polyglutamine expansion is likely to confer novel toxic properties to huntingtin. A gain of 
function mechanism is indeed supported by several data.  
Mutant huntingtin has been found to rescue embryonic lethality of knock-out mouse, 
indicating that the HD mutation does not impair normal embryonic huntingtin functions 
(Duyao, 1995; Nasir 1995). In humans, a partial deletion of the distal part of the chromosome 
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4p16.3, which includes the HD gene, results in the Wolf Hirschhorn Syndrome that is 
characterized by growth and mental retardation and a premature death at 2 years, but lacks of 
a HD-like phenotype. 
On the other hand, the finding of an anti-apoptotic role for wild-type huntingtin has suggested 
that the loss of the protective functions of the wild-type protein may participate to the disease 
mechanisms (Rigamonti, 2000; Leavitt, 2001). 
In HD target neurons, the trigger event driven by mutant huntingtin is likely to occur many 
years before the onset of the first signs of neurodegeneration leading to specific neuronal 
dysfunction. Subsequently, in debilitated neurons, other factors may participate in the disease 
cascade that leads to neuronal death.  
HD pathogenesis can be viewed as a cascade of events that is first triggered by mutant 
huntingtin through an abnormal interaction with an as yet unknown cellular constituent. Once 
triggered, this cascade broadens with time, leading eventually to neuronal death (MacDonald, 
2003).  
Several mechanisms of mutant huntingtin toxicity have been proposed, which partially fit with 
clinical data obtained from HD patients. Proposed mechanisms of cell dysfunction in HD 
include, among others, apoptotic insult, defect in protein degradation, aggregation, 
transcription dysregulation, alteration in intracellular trafficking, glutamate mediated 
excitotoxicity, mitochondrial dysfunction and oxidative stress (Fig. 3).  
These different toxic mechanisms could participate synergistically in the pathology or be 
subordinate to one of them. 
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Figure 3:  Mutant huntingtin is prone to modifications and induces many intracellular defects. Full-length 
huntingtin is cleaved by proteases in the cytoplasm, leading to the formation of cytoplasmic and 
neuritic aggregates. Mutant huntingtin also impairs calcium homeostasis and alters vesicular transport 
and recycling. Defect in BDNF transport reduces trophic support and increases neuronal death 
susceptibility. Whereas cytoplasmic and intranuclear aggregates are not directly toxic, neuritic 
aggregates could physically block transport. N-terminal fragments containing the polyQ stretch 
translocate to the nucleus where they impair transcription and induce neuronal death. In an attempt to 
eliminate the toxic huntingtin, fragments are ubiquitinated and targeted to the proteasome for 
degradation. Intranuclear aggregates could represent temporary storage of soluble and oligomeric 
forms before degradation or when the proteasome becomes less efficient (Borrell-Pages, 2006b). 
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Proteolytic cleavage, protein aggregation and the UPS 
The identification of N-terminal huntingtin fragments in neuronal intranuclear inclusions 
(NIIs) of HD postmortem brains have implicated proteolytic cleavage of the protein in HD 
toxicity (DiFiglia, 1997). Several proteases cleave huntingtin in vitro and in vivo: these 
proteases include caspase 1, 3, 6, 7 and 8, calpain and non-identified aspartyl-proteases 
(Gafni, 2004; Hermel, 2004) (Goldberg, 1996; Lunkes, 2002; Graham, 2006). Mutant 
huntingtin cleavage occurs both in transgenic animals and in HD patients (Sieradzan, 1999). 
The cleavage of huntingtin into fragments containing the polyQ stretch and their subsequent 
translocation to the nucleus is likely to be a key step in the disease progression (Saudou, 
1998). When proteolysis is prevented by inhibition of caspase or calpain activity or by 
modifying the consensus cleavage site in huntingtin, mutant huntingtin toxicity is reduced and 
disease progression is slowed (Wellington, 2000; Gafni, 2004; Luo, 2005; Graham, 2006).  
How these proteases contribute to the pathological process is not fully understood but recent 
studies suggest that not all the N-terminal fragments that result from proteolysis are toxic. 
Mice expressing mutant huntingtin, resistant to cleavage by caspase 6 but not caspase 3, 
maintain normal neuronal function and do not develop striatal neurodegeneration (Graham, 
2006).  
Once in the nucleus, huntingtin fragments may aberrantly interact with several transcription 
factors and form inclusions.  
 Neuronal inclusions have been found in HD postmortem brains (Fig. 4) and in mouse models 
of the disease. Neuronal Intranuclear Inclusions (NIIs) are a pathological hallmark of HD, and 
of other polyQ disorders. It is well known that these structures are dynamic and that the 
pathway from soluble huntingtin to inclusion bodies formation is a multi-step process where 
many different species are formed before the mature inclusion. The relevance of aggregate 
formation to the pathogenesis of HD is not totally understood.  
 
 
Figure 4:  Huntingtin immunoreactivity in HD postmortem brain. (A) 
Cortex of a juvenile patient shows numerous hNIIs prominently 
stained. (B) Cortical pyramidal neurons contain one hNII. (C) 
Striatal neurons with hNIIs. A, bar=50µm; B, bar=10µm 
(Adapted from (DiFiglia, 1997). 
 15 
Aggregates are not directly correlated with neuronal death, as the highest percentage of NII-
containing neurons in HD postmortem brain is found in non-degenerating regions (Gutekunst, 
1999). Moreover, in mouse models of HD, NIIs are not related to cell death (Kim, 1999; Slow, 
2005), and transgenic mice expressing mutant huntingtin exon 1 display only little evidence of 
cell loss despite a high percentage of intranuclear inclusions (Mangiarini, 1996). Interestingly, 
in contrast to NIIs, the presence of neuropil aggregates correlates better with HD 
neuropathology (Gutekunst, 1999). For these considerations, aggregates have been proposed 
to represent a neuroprotective cellular strategy aimed to reduce the pool of soluble toxic 
protein.  
On the other end, other evidences associate mutant huntingtin aggregates to neuronal 
dysfunction. Indeed, NIIs have been found to sequester important transcription factors, 
leading to transcriptional abnormalities. In addition, the accumulation of large aggregates has 
been proved to physically impair intracellular transport by blocking axonal and dendritic 
trafficking (Gunawardena, 2003; Lee, 2004). 
Aggregation is a characteristic of abnormally folded proteins. Inclusions have been found to 
be immunopositive for ubiquitin and chaperones, suggesting that the mutant protein is 
recognized as misfolded and is targeted for degradation to proteasome (Davies, 1997; 
DiFiglia, 1997; Wyttenback, 2000). Recent data have shown that expanded polyglutamine 
sequences cannot be digested by proteasome, which therefore release undigested polyQ-
containing fragments for further hydrolysis by still unidentified peptidases (Holmberg, 2004; 
Venkatraman, 2004). The occasional failure of fragments to be rapidly released may 
compromise proteasome function and accelerate the accumulation of polyQ proteins. These 
findings hence support the hypothesis that the ubiquitin-proteasome system (UPS) is impaired 
by polyQ expansions, strongly indicating that the protein turnover is affected in polyglutamine 
diseases (Bence, 2001). However, controversial results about the impaired proteasome activity 
in response to mutant huntingtin expression have been reported (Bence, 2001; Jana, 2001; 
Bowman, 2005; Bett, 2006). 
Autophagy and ER stress in HD 
Proteasome is unable to degrade protein complexes, aggregates or oligomers (Verhoef, 2002). 
Several evidences have suggested a central role of autophagy in degradation of disease-
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associated proteins (Ravikumar, 2002; Rubinsztein, 2006; Settembre, 2008). Autophagy is a 
bulk degradation process involved in the clearance of long-lived proteins, protein complexes 
and organelles. Evidences of autophagy in HD brain as well as in cellular and animal models 
have been demonstrated (Larsen, 2002; Kegel, 2000; Petersen, 2001). Furthermore, induction 
of autophagy by treatment with the mTOR inhibitor rapamycin has been demonstrated to 
reduce aggregation and attenuate toxicity in HD cells and mouse models (Ravikumar, 2004). 
Evidence is beginning to emerge indicating that clearance pathway responsible for elimination 
of aggregates are closely regulated by the ER through the UPR (Unfolded Protein Response) 
stress sensors, such as IRE1α and PERK/eIF2α (Kouroku, 2007). Studies aimed to understand 
the function of wild type huntingtin demonstrated that inhibition of its expression significantly 
alters the ER morphogenesis (Hilditch-Maguire, 2000; Omi, 2005). In addition, mutant 
huntingtin perturbs ER calcium homeostasis (Rockabrand, 2007), and the experimental 
targeting of N-terminal mutant huntingtin fragments to the ER decrease its aggregation 
propensity (Rousseau, 2004). Thus, increasing evidences suggest that mutant huntingtin may 
exert its neurotoxic effect by directly causing ER stress. The accumulation of mutant 
huntingtin inclusions has been shown to trigger activation of the UPR in vitro (Kouroku, 
2007; Reijonen, 2007) and subsequently autophagic clearance of such aggregates (Kouroku, 
2007; Hoyer-Hansen, 2007, Hoyer-Hansen 2007b). Cytoplasmic aggregates stimulate ER 
stress signal and induce ER-stress-mediated cell death with caspase-12 activation in mouse 
cells, presumably by the accumulation of unfolded protein in the ER due to the inhibition of 
retrotranslocation and ER-associated ubiquitin/proteasome degradation (ERAD) (Kouroku, 
2000). 
Despite this evidence, the actual involvement of ER-stress related pathways in the disease 
remains speculative, as no in vivo experiments have validated these findings. 
Transcriptional dysregulation 
Transcriptional dysregulation has emerged as a pathogenic mechanism involved in HD. The 
majority of transcription factors interacting with huntingtin associate with the N-terminal 
region of the protein and the interactions are in some cases altered by the polyQ expansion 
(Steffan et al., 2000; Dunah et al., 2002). So far, the transcription factors that have been found 
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to interact with huntingtin include Sp1, CBP, p53, mSin3A, NCoR, CtBP, CA150, p300/CBP 
associated factors (P/CAF), TAFII130, NF-Y and REST/NRSF. 
The CRE pathway is very interesting for its role in controlling the expression of neuronal 
genes and neuronal survival. Intriguingly, deletion of CREB causes selective 
neurodegeneration in the hippocampus and striatum inducing neurological phenotypes 
resembling those in HD (Mantamadiotis, 2002).  
Soluble mutant huntingtin interacts with both the glutamine-rich activation domain and the 
acetyltransferase domain of the co-activator CREB-binding protein (CBP) altering its function 
(Steffan, 2001).  
Mutant huntingtin binds p53 and induces its stabilization and transcriptional activity toward 
proapoptotic genes such as Bax and Puma (Bae, 2005). 
The Sp1/TAFII130 (TATA-binding protein (TBP)-associated factor) pathway is also altered 
by soluble mutant huntingtin in a polyglutamine dependent manner, leading to transcriptional 
downregulation of the nerve growth factor and dopamine D2 receptors (Dunah, 2002; Li, 
2002).  
Dysregulation of transcription may also result from abnormal interaction between mutant 
huntingtin and repressors or activators within the nucleus, such as the nuclear receptor 
corepressor N-CoR (Boutell, 1999), the transcriptional co-repressor C-terminal binding 
protein (CtBP) (Kegel, 2002), the activator CA150 (Holbert, 2001).  
Furthermore, within the nucleus, mutant huntingtin fragments form aggregates which have 
been shown to sequester transcription factors, as in the case of CBP and NF-Y (Nucifora, 
2001; Yamanaka, 2008). 
Transcriptional alteration also derives from atypical behavior of mutant huntingtin in the 
cytoplasm of the cells, as occurs for the repressor element-1 transcription factor/neuron 
restrictive silencer factor (REST/NRSF) which shows reduced binding to mutant huntingtin 
with respect to the wild type. Wild-type huntingtin, but not the mutant, promotes BDNF 
(Brain Derived Neurotrophic Factor) transcription by sequestering REST/NRSF in the 
cytoplasm thereby preventing it from forming the nuclear co-repressor complex at the NRSE 
nuclear site and allowing gene transcription (Zuccato, 2003). 
Consistent with transcriptional repression playing a role in the pathogenesis of HD, decreased 
acetylation and increased methylation of histones have been found in HD experimental 
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models and HD patients (Steffan, 2001; Ferrante, 2003; Ryu, 2006). The HD protein, indeed, 
binds the acetyl transferase domain of different transcription factors such as CBP and 
p300/CBP Associated Factor (P/CAF), affecting acetylation of histones (Steffan, 2001), 
whereas increased level of histone methyl transferase, as ESET, have been reported to affect 
chromatin structure and, finally, gene transcription in HD patients and mouse models (Ryu, 
2006). 
Intracellular trafficking deficiencies 
Altered intracellular dynamics involving defects in axonal transport or alterations of the 
secretory and endocytic pathways are likely to participate in HD pathogenesis. 
The main evidence of a role for huntingtin in cellular trafficking came from the 
characterization of the first huntingtin partner HAP1. The precise role of this protein in 
neurons remains to be explored, although some studies have shown that HAP1 is involved in 
endocytosis, vesicular trafficking and Ca2+ regulation (Gauthier, 2004; Kittler, 2004). The 
binding of HAP1 to huntingtin is enhanced by the expanded polyQ tract (Li, 1995). Mutant 
huntingtin potentially either disrupt the interaction of HAP1 with other molecules or sequester 
HAP1-associated protein complexes, thereby affecting HAP1-associated trafficking (Rong, 
2007). This idea is supported by the finding that mutant huntingtin attenuates BDNF transport 
by dissociating htt-HAP1-p150Glued complex from microtubules. Decreased BDNF transport 
has been linked to loss of neurotrophic support and increased neuronal toxicity (Gauthier, 
2004). 
Huntingtin is located on plasma and intracellular membranes and associates with vesicles and 
different organelles (DiFiglia, 1995; Velier, 1998). Sequences in the N-terminal region of 
huntingtin have been demonstrated to modulate such interactions by being substrate of  
HIP14, a palmitoyl transferase (Yanai, 2006). Expansion of the polyQ tract results in reduced 
interaction between mutant huntingtin and HIP14 with consequent reduction of palmitoylation 
which leads to inclusion formation and increase in neuronal toxicity. 
Finally, huntingtin interacts with many proteins involved in secretion and endocytosis. 
Reduced endosomal motility and endocytic activity in HD fibroblasts and mutant cells was 
indeed recently reported (Pal, 2006).  
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Mitochondrial impairment, oxidative stress and excitotoxicity 
Striatal vulnerability to mitochondrial impairment was discovered after the intoxication with 
3-nitropropionic acid (3-NP) (see also 1.3). This toxin leads to a severe neurological disease 
resembling HD, with a degeneration of basal ganglia and movement dysfunctions 
characterized by dystonia, chorea and hypokinesia (Ludolph, 1991; Alexi, 1998). A 
generalized mitochondrial impairment occurs in HD patients and in mouse models of the 
disease where reduced levels of ATP and membrane potential of mitochondria have been 
reported (Panov, 2002; Gines, 2003). 
Both wild-type and mutant full-length huntingtin are associated with the mitochondrial outer 
membrane (Choo, 2004). It has been shown that mutant N-terminal huntingtin fragment 
decreases the calcium threshold required to induce mitochondrial permeability transition 
(MPT) pore opening. This coincides with cytochrome c release and thus activation of 
apoptotic death pathways, including activation of caspases (Choo, 2004), calpain (Bizat, 
2003), and p53 (Bae, 2005).  
Furthermore, the expression of expanded polyQ proteins in PC12 cells and in fibroblasts of 
HD patients leads to production of reactive oxygen species (ROS) and thus to the activation of 
DNA damage response (Giuliano, 2003).  
The decreased ATP/ADP ratio was linked to enhanced calcium influx through NMDA 
receptors (Seong, 2005). Impaired energy metabolism probably leads to reduced ATP 
production, with a concomitant reduced mitochondrial membrane potential and a higher 
vulnerability to NMDA-mediated calcium influx and excitotoxicity (Panov, 2002; Seong, 
2005). Calcium influx could trigger further free radicals production exacerbating cell damage. 
As cortical glutamatergic processes massively innervate the striatum, it is a structure at risk of 
glutamate-mediated excitotoxic injury. The overactivation of NMDA glutamate receptors 
allows high levels of calcium entry, resulting in the death of MSNs (Ferrante, 1985; Lipton 
and Rosenberg, 1994). Significant increases in the NMDA receptor density associated with an 
increase of intracellular free calcium levels were found in MSNs from several mouse models 
for HD (Levine, 1999; Cepeda, 2001; Zeron, 2002).  
At a molecular level, huntingtin interacts with postsynaptic density 95 (PSD-95), a scaffold 
protein that causes clustering and activation of receptors in the postsynaptic membrane, 
modulating excitatory signaling through the interaction with NMDA receptors (Sun, 2001). 
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Enhanced activation of NMDA receptors may also reflect an altered interaction of mutant 
huntingtin with PSD95. 
Loss of normal huntingtin function 
The hypothesis that a loss of normal huntingtin function may play a role in HD pathology 
came after the finding that huntingtin is an indispensable protein with antiapoptotic function 
(Rigamonti, 2000). Wild-type huntingtin overexpression was found indeed to be 
neuroprotective in striatal cells exposed to various apoptotic stimuli such as serum deprivation 
or 3-nitropropionic acid treatment (3-NP) (Rigamonti, 2001). Overexpression of wild-type 
huntingtin was also found to protect in vivo against ischemic injury or NMDA receptor-
mediated excitotoxicity (Zhang, 2003; Leavitt, 2001; Cattaneo, 2001; Leavitt, 2006). 
In addition, postnatal inactivation of huntingtin in mouse neurons resulted in a progressive 
degenerative neuronal phenotype further underlying the role of huntingtin in the surviving of 
adult neurons (Dragatsis, 2000). 
The antiapoptotic effect may occur via the sequestration of proapoptotic molecules such as 
Hip1 that, once dissociated from huntingtin, forms a complex with Hippi and activates caspase 
8 (Gervais, 2002).  
The protection of wild-type huntingtin may also occur by activation of BDNF transcription 
through the interaction with REST and by the stimulation of the vesicular BDNF transport 
along microtubules (Zuccato, 2001; Zuccato, 2003; Gauthier, 2004).  
1.3 From chemical to genetic models of HD 
A large contribution in elucidating toxic mechanisms involved in HD derives from studies in 
cellular and animal models of the disease.  
Before the emergence of genetic models, different toxins were delivered to rodents and 
primates to reproduce HD-like phenotypes (Brouillet, 1999).  
Glutamate receptors may be over-stimulated with excitatory amino acids such as ibotenic 
acid, kainic acid, NMDA or quinolinic acid, inducing neuronal death by excitotoxicity (Bruyn 
and Stoof, 1990). Another strategy to induce striatal degeneration consists in the systemic 
administration of mitochondrial blocker 3-nitroproprionic acid (3-NP), which inhibits 
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succinate dehydrogenase, leads to ATP depletion, and reproduces a specific striatal 
degeneration of GABAergic neurons.  
These chemically induced models were, and still are, useful tools to test therapeutic strategies 
of interest for HD. On the other hand, these models do not reproduce the progressive chronic 
neuronal degeneration and lack the genetic component of HD. Therefore, their interest has 
decreased in favor of HD gene-based models. 
1.3.1 Genetic animal models 
A substantial number of animal models of HD is available to conduct studies aimed at 
understanding and eventually ameliorating the human disease. Differences among these model 
systems include the length of the huntingtin transprotein, length of polyglutamine repeat, 
origin of the mutated huntingtin in the species, host organism species and strain and levels of 
huntingtin expression. 
The nematode Caenorhabditis elegans, with only 302 neurons, is the simplest genetic animal 
model of HD (Faber, 1999; Holbert, 2001b; Parker, 2001) that can be used for biochemical, 
morphological and behavioral studies. In addition, its transparency allows longitudinal live 
imaging studies in vivo with standard microscopy equipment. 
Drosophila melanogaster is particularly suitable for measuring degeneration of 
photoreceptors and motor function (Jackson, 1998; Steffan, 2001; Gunawardena, 2003). 
PolyQ-expressing flies form nuclear inclusions and undergo a progressive neurodegeneration 
which leads to early cell death.  
Mouse models, because of their close genetic and physiological similarities to humans, have 
been developed as the best mammalian model system for genetic diseases.  
The first transgenic HD mouse model was generated in 1996. These mice express the exon 1 
of human huntingtin with 115 CAG (strain line R6/1) or 155 CAG (strain line R6/2) repeats 
and exhibit a severe and rapidly declining molecular and behavioral phenotype, although little 
evidence for cell loss can be found (Mangiarini, 1996; Murphy, 2000; Turmaine, 2000; van 
Dellen, 2000). 
Various other mouse lines have been developed thereafter, each characterized by different 
promoter, expression levels, huntingtin length and polyQ expansion (Tab. 3).  
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Transgenic rat model, which has been also developed, shows phenotypes similar to transgenic 
mice (von Horsten, 2003). 
CAG Hdh knock-in mice 
Knock-in mice with the murine protein bearing polyQ expansion are close models of the HD 
genetic state, as they express mutant huntingtin at endogenous levels.  
Hdh knock-in mice carrying different expanded CAG repeats have been generated by distinct 
laboratories. Similarities between these lines have been reported with respect to inclusion 
formation, brain atrophy, tremors, hyperactivity and clasping phenotype (Tab. 3).  
 
Tab. 3:  Genetic mouse models of Huntington’s disease. The table recapitulates the major characteristics of the 
available transgenic and knock-in mouse models of Huntington’s disease (Adapted from 
http://www.hdfoundation.org/PDF/hdmicetable.pdf). 
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In this work we have used Hdh knock-in mice generated in the laboratory of Marcy 
MacDonald (White, 1997), that express endogenous levels of wild-type (HdhQ7) or mutant 
(HdhQ111) huntingtin. As in humans, Hdh knock-in mice with elongated CAG repeat (HdhQ111) 
presents striatal neuronal degeneration, gliosis, and gait abnormalities at older age (24 
months) (Wheeler, 2000). In these mice survival is not compromised, but well before the first 
signs of neurodegeneration they show early molecular phenotypes evident both in 
heterozygous (HdhQ7/111) and homozygous (HdhQ111/111) offspring. These changes are first 
apparent in the striatum, and involve medium spiny projection neurons although at later age 
other brain regions are involved (MacDonald, 2003).  
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Figure 5:  Temporal disease cascade in HdhQ111 mice (Adapted from (MacDonald, 2003). 
As depicted in Fig. 5 early phenotypes of HdhQ111 mice include upregulation of Rrs1 mRNA 
at 3 weeks of age (a), accumulation of full-length mutant huntingtin in the nucleus of MSNs at 
6 weeks of age (b), decreased [ATP/ADP] ratio and cAMP levels (c), reduced cAMP 
signaling via PKA/CBP/CREB with reduction of BDNF (d). These events precede 
intranuclear inclusions (e), neuropil aggregates (f) reactive gliosis with neuronal cell 
dysmorphology (g) and gait deficit (h).  
Cell models 
HD cell models are mainly obtained by expression of mutant huntingtin in different cell types, 
including yeast, cell lines, or primary cultures.  
Several mammalian cell lines stably over-expressing mutant or wild-type huntingtin have 
been developed (Lunkes and Mandel, 1998; Jana, 2000; Rigamonti, 2000; Wyttenbach, 2001).  
Neuronal cell lines obtained from Hdh knock-in mice are of particular interest because 
express wild-type and mutant huntingtin at endogenous level and therefore provide genetically 
precise HD neuronal cell culture models for cell biology and biochemistry. 
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STHdh striatal cells 
In this work we have used immortalized STHdhQ7 and STHdhQ111 cell lines, generated from 
striatal primordia of wild-type HdhQ7 and mutant HdhQ111 knock-in mouse embryos, 
respectively (Trettel, 2000). STHdhQ111 striatal cells present an altered nuclear and 
cytoplasmic distribution of full-length mutant protein. Mutant clones exhibit stress responses 
that include: elevated levels of p53, an enlarged ER compartment, and an increased basal 
activity of the iron pathway (Trettel, 2000). Furthermore, reduced concentration of ATP and 
cAMP in mutant cells suggest impaired energy metabolism. Activation of the Akt pro-survival 
pathway in mutant striatal cells reflects enhanced NMDA receptor signaling, with 
excitotoxicity due to aberrant Ca2+ influx (Gines, 2003). In addition, as in the human disease, 
decreased levels of BDNF in STHdhQ111 cells are evident and associated with altered sub-
cellular localization of REST (Zuccato, 2003). These abnormal phenotypes are found both in 
homozygous and heterozygous mutant clones, suggesting a mechanism that conforms to HD 
genetic criteria. Thus STHdhQ111 striatal clones represent a useful cellular model to explore 
biochemical pathways involving mutant huntingtin and to test hypothesis on the HD-trigger 
mechanism. 
1.3.2 Microarray analysis of HD brains and animal models 
Characterization of neurotransmitter receptor levels in human HD brains provided the first 
evidence that transcriptional dysregulation might have a role in HD pathogenesis (Augood, 
1997). To elucidate the molecular phenotypes of HD on a genome-wide scale different 
microarray analyses have been performed both from HD brains and from HD mouse models. 
The first data set came from a study performed in the striata of R6/2 mice (Luthi-Carter, 
2000). This analysis suggested that the dysregulation of the mRNAs encoding 
neurotransmitter receptors and related second messenger system is an early component of the 
pathological processes (Luthi-Carter, 2000). More recently, Affymetrix transcription profiles 
have been generated to compare expression pattern of different brain regions from a large set 
of HD autopsy brains (Hodges, 2006). Hodges and co-workers found that the transcriptional 
pathology of HD shows a distinct regional pattern that parallels the known pattern of 
neurodegeneration: caudate>motor cortex>cerebellum, and a strikingly similar gene 
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expression profiles of HD caudate and HD motor cortex. This overlap suggested a shared 
molecular mechanism of HD-related dysfunction in both regions, despite the fact that the HD-
sensitive (glutamatergic) corticostriatal pyramidal neurons have a different neurochemistry 
than that of HD-sensitive (GABAergic) medium spiny neurons of the caudate (Hodges, 2006). 
Gene ontology analysis of differentially expressed genes suggested increased expression of 
genes related to central nervous system development in both caudate and motor cortex. 
Consistent changes in expression were even observed in individual cells and thus the reported 
decreases in expression in the caudate do not simply reflect cell loss (Hodges, 2006). 
In a recent work, seven genetic mouse models of HD and postmortem human HD caudate 
were compared for changes in mRNA levels (Tab. 4).  
A global view suggested that all mutant huntingtin-expressing mice would show relevant 
mRNA changes if the rodent lifespan allowed sufficient disease progression (Kuhn, 2007).  
The similarity between the transgenic models and human HD was much stronger for the genes 
that are down-regulated with the disease. Surprisingly, no differences between models 
expressing an N-terminal fragment and those expressing a full-length huntingtin protein were 
observed (Kuhn, 2007; Woodman, 2007). This suggested that these effects are caused by the 
polyQ-bearing region of the protein. On the other hand, the more protracted timeline of this 
effect in the full-length models is consistent with the hypothesis that transcriptional 
dysregulation is dependent on the nuclear accumulation of a proteolytically derived N-
terminal huntingtin fragment (Kuhn, 2007). 
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Tab. 4:  Top-ranked early mouse changes concordant with human caudate (Adapted from (Kuhn, 2007) 
1.4 Toward therapies for HD 
Currently, there is no effective therapeutic treatment for preventing or delaying the 
progression of the disease. Patients are treated with general symptomatic and non-specific HD 
drugs, such as antidepressants or neuroleptics. 
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Different drugs, targeting one or more cellular pathway affected by mutant huntingtin, have 
been proposed and are currently studied (Tab. 5).  
As the mutant protein in HD misfolds and aggregates, promoting the degradation of the toxic 
protein may be of beneficial effect. Many different approaches have been tried to this aim, 
such as activation of chaperones by geldanamycin. The treatment induces expression of heat 
shock proteins, which promote the heat shock response leading to degradation through the 
proteasome of misfolded proteins (Sittler, 2001). Another approach is to directly target the 
proteasome to induce the degradation of toxic soluble proteins (Ciechanover, 2003). 
Compounds as rapamycin, by activating autophagy, have been found to promote the clearance 
of aggregates (Ravikumar, 2004). 
Chemical compounds that inhibit histone deacetylase might compensate the decrease in the 
acetylation of histones and the repression of gene transcription caused by the polyQ expansion 
(Steffan, 2001). They have been found to reduced polyglutamine toxicity in HD models 
(Ferrante, 2003; Hockly, 2003).  
 
Tab. 5:  Possible therapeutic compounds for HD (Borrell-Pages, 2006b). 
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Evidence of apoptosis in HD postmortem brains suggested the use of apoptosis inhibitors. The 
antibiotic minocycline, which possesses antiapoptotic and anti-inflammatory properties, may 
be beneficial in HD (Chen, 2000). Although some studies showed opposing results (Diguet, 
2003), clinical trials are ongoing and may validate the use of this drug in patients (Bonelli, 
2004).  
Drugs that improve mitochondrial function, such as coenzyme Q10, a carrier for electron-
transfer in the mitochondrial membrane, and creatine, which may stabilize the mitochondrial 
permeability transition, have been also studied (Verbessem, 2003; Schilling, 2001). These 
compounds have been proved to be neuroprotective in the transgenic mouse model R6/2 
(Ferrante, 2002).  
Cystamine is an inhibitor of the transglutaminase (TGase), a calcium-dependent enzyme that 
is upregulated in the brains of HD patients and HD mice (Karpuj, 1999). Cystamine inhibits 
also caspase 3 activity (Lesort, 2003), prevents mitochondrial depolarization (Mao, 2006), 
increases the levels of antioxidants (Fox, 2004), and the secretion and release of BDNF 
(Borrell-Pages, 2006a).  
Neurotrophic factors, such as BDNF and the ciliar neurotrophic factor (CNTF), have been 
shown to have neuroprotective effects in mouse models of HD (Canals, 2004; Bloch, 2004). 
The antidepressant paroxetine was identified as a compound that enhances the production or 
secretion of BDNF (Duan, 2004).  
Finally, a promising approach is the reconstruction of neuronal circuits in the brains by 
intrastriatal transplantation of striatal neuroblasts from human fetuses (Peschanski, 2004). 
Patients show motor, functional and cognitive improvement, and the transplanted neurons 
partially rescue the cortico-striatal loop. However, precautions are needed since there are still 
not enough data to judge the final fate of the transplanted neurons and the clinical 
improvements might not be permanent (Bachoud-Levi, 2006). 
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1.5 Aims of this work 
HD pathogenesis can be viewed as a cascade of events that is first triggered by mutant 
huntingtin through an abnormal interaction with a yet unknown cellular constituent. Once 
triggered, this cascade broadens with time, leading first to neuronal dysfunction and 
subsequently to neuronal death. According to this model, mutant huntingtin might participate 
either in the trigger mechanism that initiates the disease process or in the myriad subsequent 
downstream events on the way to cell death (MacDonald, 2003). Several hypotheses have 
been proposed to elucidate the mechanisms of HD pathogenesis, including excitotoxicity, 
oxidative stress, impaired energy metabolism, abnormal protein aggregation, transcription 
dysregulation and abnormal protein interactions. However, because of the incomplete 
understanding of the interplay among toxic mechanisms in the HD cascade, treatment to delay 
the onset or slowdown progression remains unavailable at present. 
In this context, the description of mutant huntingtin-dependent molecular events is crucial to 
provide a comprehensive picture of the HD pathogenic mechanisms and to design new 
therapeutic interventions for this incurable disease. 
 
In this thesis we have taken into account two complementary studies aimed to investigate 
disease causing molecular mechanisms. 
1. The role of Pin1 in Huntington's disease. 
Here we focus our attention on a newly identified huntingtin partner (unpublished data, 
Michelazzi S., PhD thesis), the peptidyl-prolyl cis-trans isomerase Pin1. Pin1 activity has 
been reported to modulate several cellular processes, including neurodegeneration. In the 
present work we explore the involvement of Pin1 in HD pathogenic mechanisms. 
2. The role of Rrs1 in Huntington's disease. 
In a previous work, the upregulation of Rrs1 mRNA was identified in a pre-symptomatic 
mouse model of HD as the earliest detectable event in the HD cascade (Fossale, 2002). 
Rrs1 protein has been characterized so far only in yeast where it participates in ribosome 
biogenesis. Here we aim to characterize Rrs1 protein in mammalian cells and to 
investigate its role in the early phase of the disease process. 
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CHAPTER 2: ROLE OF PIN1 IN HD 
2.1 INTRODUCTION 
Proline residues have the unique property of existing in two isomers (Fig. 6) and can provide a 
potential backbone switch in the polypeptide chain controlled by cis-trans isomerization of the 
peptidyl-prolyl bond. These residues, following a phosphorylated Ser/Thr, are consensus 
binding site for the peptidyl-prolyl isomerase Pin1 (protein interacting with NIMA (never in 
mitosis A)-1), which catalyzes the cis-trans isomerization of the proline bond. This event 
couples phosphorylation at these sites with profound changes in protein conformation and has 
emerged recently as a pivotal signaling mechanism in several processes, such as cell growth 
regulation, stress responses and neuronal survival.  
 
 
 
Figure 6:  Proline is unique among amino acids in its ability to adopt either the cis or trans state of the backbone 
torsion angle, due to its five-membered ring in the peptide backbone. Uncatalyzed isomerization is a 
rather slow process but can be greatly accelerated by peptidyl-prolyl cis/trans isomerases (PPIases). 
Pin1 belongs to the parvulin subfamily of PPIases, and is the only phosphorylation-specific PPIase. 
Pin1 specifically recognizes phosphorylated Pro-Ser/Thr (pSer/Thr-Pro) peptide sequences and 
catalyzes the cis-trans conformational changes of the proline bond, thereby modulating the function 
of its substrates (Adapted from (Lu and Zhou, 2007). 
Although Pin1 belongs to the parvulin subfamily of PPIases, it is the only PPIase that 
specifically recognizes phosphorylated Pro-directed Ser/Thr (pSer/Thr-Pro) motifs (Lu, 1996). 
This enzyme is a rather small protein (18kDa) present both in nucleus and cytoplasm. Pin1 
binds the phosphorylated site of target substrates through its WW domain, while catalyzes the 
cis-trans transition of the proline bond through the isomerase (PPIase) domain (Lu, 1999b). 
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The change in conformation catalyzed by Pin1 has been shown to perturb protein stability, 
post-translational modifications and protein interactions of its substrates, that include p53, 
p73, c-jun, cyclin D1, beta-catenin, bcl-2 and other factors involved in diverse cellular 
processes (reviewed in (Lu and Zhou, 2007) like cell-cycle control, transcription and splicing 
regulation, DNA damage response, neuronal survival, and germ cell development (Zacchi, 
2002; Atchison, 2003; Wilcox, 2004; Dougherty, 2005). Notably, aberrant Pin1 function has 
been implicated in several human diseases, including cancer and neurodegenerative disorders. 
While in normal tissues its expression is associated with cell proliferation, in human cancer 
Pin1 is prevalently over-expressed working as a critical catalyst for multiple oncogenic 
pathways (Wulf, 2001; Ryo, 2001; Ayala, 2003). Interestingly, Pin1-deficient mice have been 
found to be resistant to tumorigenesis induced by specific oncogenes (Liou, 2003), while 
showing age-dependent neurodegeneration (Wulf, 2004). 
2.1.1 Pin1 and neurodegeneration 
Pin1 dysfunction has a prominent role in age-dependent neurodegeneration and in 
neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson’s diseases (PD) and 
Amyotrophic Lateral Sclerosis (ALS). 
In AD brains, Pin1 has been shown to regulate dephosphorylation and function of hyper-
phosphorylated forms of tau and of amyloid precursor protein (APP) (Lu, 1999a; Liou, 2003).  
Since phosphatases such as PP2A can only dephosphorylate pSer/Thr-Pro motifs in the trans 
conformation, Pin1-induced conformational changes may facilitate the dephosphorylation of 
its substrates (Zhou, 2000). Therefore, a loss of Pin1 function can lead to a build-up of cis-
pSer/Thr-Pro motifs. Cis-pAPP is processed by the amyloidogenic pathway, which leads to 
the accumulation of amyloid- (A) peptides and the formation of amyloid plaques. Cis-pTau 
is resistant to protein phosphatases (PPases), which leads to a loss of microtubule (MT) 
binding, hyperphosphorylated tau and the formation of neurofibrillary tangles. The formation 
of tangles and plaques might further reduce Pin1 function by sequestering Pin1 and inducing 
its oxidative modification in a positive feedback loop.  
In addition, a lack of proper Pin1 function may lead to further activation of mitotic kinases, 
which may further increase the phosphorylation of tau, APP and other proteins, eventually 
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causing neuronal death. Therefore, Pin1 deregulation might act on multiple pathways to 
contribute to AD pathogenesis and may link both tangle and plaque pathologies. 
In PD Pin1 accumulates in Lewy bodies (LB) and its overexpression enhances the protein 
half-life and insolubility of -synuclein (Ryo, 2006). By binding to synphilin-1, a -synuclein 
partner, Pin1 enhances its interaction with -synuclein, thus facilitating the formation of -
synuclein inclusions (Fig. 7). 
 
 
Figure 7:  Schematic representation of Pin1-mediated 
mechanism in PD. Pin1 binds phosphorylated 
synphilin-1, an -synuclein partner, via its Ser-
211-Pro and Ser-215-Pro motifs and enhances 
its interaction with -synuclein, thereby 
facilitating the formation of -synuclein 
inclusions (Ryo, 2006). 
 
 
Pin1 also colocalized with ALS-affected spinal cord neuronal inclusions and its inhibition 
reduced glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in 
neurons (Kesavapany, 2007). 
2.1.2 Pin1-/- mice 
In a first characterization, Pin1-/- mice were reported to develop normally till the age of six 
months (Fujimori, 1999). 
In a following study, by Liou and co-workers, Pin1-/- mice displayed many severe cell-
proliferative abnormalities, including decreased body weight, retinal degeneration, mammary 
gland retardation, and testicular atrophy (Liou, 2002). 
After the implication of Pin1 in Alzeimer’s Disease (Lu, 1999), a role for Pin1 in 
neurodegeneration was postulated. 
In normal conditions, Pin1 expression showed a subregional difference in hippocampus and 
parietal cortex (Liou, 2003). The subregions with low expression of Pin1 are known to be 
prone to neurofibrillary degeneration in AD, whereas those containing high Pin1 expression 
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are spared, suggesting the existence of an inverse correlation between Pin1 expression and 
predicted neuronal vulnerability (Holzer, 2002). 
Concomitantly with these findings, Pin1-/- mice showed progressive age-dependent motor and 
behavioral deficits. Furthermore, the number of NeuN-positive neurons was significantly 
decreased in the parietal cortex and spinal cord of old, but not young, Pin1-/- mice. However, 
no obvious neuronal loss was found in other brain regions (Liou, 2003). Degeneration was 
also observed in some axons and the presence of electron-dense structures in neuronal 
processes was reported (Liou, 2003). 
These results provided genetic evidence for the critical role of Pin1 in protecting against age-
dependent neurodegeneration. 
 
 
The results presented in this section of the thesis are part of a large interlaboratory project 
aimed to achieve an exhaustive characterization of the role of Pin1 in Huntington's disease. To 
this purpose, as part of the work performed in our laboratory, Silvia Michelazzi showed for 
the first time that Pin1 is a novel huntingtin interactor and that mutant huntingtin binding to 
Pin1 is stronger compared to wild-type (Silvia Michelazzi, SISSA PhD Thesis 2007).  
In this thesis we focused our attention on the functional aspects that Pin1 might cover in the 
context of Huntington's disease.  
1. The broad range of cellular pathways in which the prolyl-isomerase Pin1 has been 
implicated, in particular its characterization as an important player in different 
neurodegenerative disorders, prompted us to consider a role for Pin1 in mutant 
huntingtin aggregate formation. Since the exact nature and role of such aggregates in 
HD is still an open question, whereas the toxicity of the soluble monomeric protein is 
becoming a well accepted reality, we decided to test the possibility of Pin1 as a regulator 
of huntingtin stability.  
2. Pin1 has been found to alter the activity or the levels of several transcription factors. 
Since transcriptional dysregulation is an important pathogenic mechanism in HD we 
decided to asses whether Pin1 may play a role in this process. Microarray analysis is 
performed on cellular and mouse models of the disease where Pin1 gene has been 
specifically knocked down.   
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2.2 RESULTS 
2.2.1 To investigate Pin1 activity in modulating huntingtin half-life and 
aggregate formation 
Pin1 overexpression reduces mutant huntingtin aggregation 
When ectopically expressed in cell cultures, amino-terminal fragments of mutant huntingtin 
aggregate and generate nuclear and/or cytoplasm inclusions. To investigate whether Pin1 
modulates aggregate formation we have used a short huntingtin amino-terminal fragment 
(residues 1-171) with a pathogenic glutamine tract (Q60) fused at the carboxy-terminus with a 
GFP-moiety (htt1-171Q60GFP) (Persichetti, 1999). 
Hek293 cells were co-transfected with mutant huntingtin cDNA (htt1-171Q60GFP) and with a 
construct encoding for HA-tagged Pin1 (HA-Pin1) or with an empty vector (pcDNA3.0-HA) 
as control. Forty-eight hours after transfection, the proportion of inclusions-containing cells 
was evaluated by fluorescent microscopy. Interestingly, as shown in figure 8, overexpression 
of Pin1 remarkably reduces the number of transfected cells with mutant huntingtin inclusions. 
 
Figure 8:  Pin1overexpression reduces mutant huntingtin inclusions. Hek293 cells were co-transfected with htt1-
171Q60GFP and HA-Pin1 or with empty vector (pcDNA3.0-HA) as control. 48 hours after transfection 
cells were fixed and stained with anti-HA antibody. Scale bar 10 µm. The percentage of aggregates-
containing cells of total transfected cells is shown in the graph. 
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Pin1 contains an N-terminal WW domain (aa 1-40), which mediates protein interaction and a 
C-terminal peptidyl-prolyl cis/trans isomerase (PPIase) domain (aa 41-163) that catalyzes 
isomerization of its substrates (Fig. 9a). Residues Y23 and S67 of the protein have been 
implicated in regulating the binding and the catalytic activities of Pin1, respectively (Lu, 
1999b; Eckerdt, 2005; Behrsin, 2007). By site-directed mutagenesis we have inserted two 
point-mutations into Pin1 coding sequence to generate an inactive Pin1Y23A;S67E double mutant 
(HA-Pin1DM) (Fig. 9a). We then used this construct as a more appropriate negative control to 
repeat overexpression experiments with huntingtin and Pin1. 
 
Figure 9:  The inactive form of Pin1, Pin1-DM, does not affect htt1-171Q60GFP aggregate formation. (a) 
Schematic representation of Pin1-DM produced by site-directed mutagenesis. (b) 
Immunofluorescence images of Hek293 cells co-transfected with htt1-171Q60GFP and HA-Pin1 or 
HA-Pin1DM. 48 hours after transfection cells were fixed and stained with anti-HA. Scale bar 10 µm. 
(c) Percentage of aggregates-containing cells of total co-transfected cells. Error bars represent SDs 
from 3 independent experiments. (d) Filter trap assay shows absence of detectable htt1-171Q60GFP 
SDS-insoluble material in cells co-expressing HA-Pin1. Hek293 cells were co-transfected with htt1-
171Q60GFP and HA-Pin1 or HA-Pin1DM. 48 hours after transfection cells were harvested and 
processed for filter trap. Blot was probed for huntingtin with MAB5490. (e) Western blot analysis of 
whole-cell lysates probed for huntingtin (MAB5490), β-actin and Pin1 (α-HA). (b), (d) and (e) are 
representative of at least 4 independent experiments. 
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Hek293 cells were transfected with htt1-171Q60GFP and with HA-Pin1 or HA-Pin1DM. 
Fluorescent analysis was performed forty-eight hours after transfection. As above, co-
expression of Pin1 consistently decreased the number of inclusions in co-transfected cells, 
which mostly showed diffuse cytoplasmic and nuclear fluorescent distribution of the GFP-
huntingtin fragment (Fig. 9b). By contrast, the expression of the inactive Pin1DM did not 
affect inclusion formation (Fig. 9b and c). Equal transfection efficiency was ensured by 
counting the number of co-transfected cells in at least 3 independent experiments (data not 
shown). 
We then tested for insoluble complexes using a filter trap assay. SDS-resistant protein extracts 
of cells co-transfected with htt1-171Q60GFP and HA-Pin1 or HA-Pin1DM were applied to 
cellulose acetate membranes and probed with the anti-huntingtin antibody MAB5490. A 
strong positive signal for SDS-insoluble material was detected only in protein preparation 
from cells co-transfected with Pin1DM (Fig. 9d), but not with Pin1, further supporting Pin1 
activity in modulating aggregation processes. 
Huntingtin aggregation in vitro and in vivo is dependent on length of the polyglutamine tract, 
on time and protein concentration (Wanker, 2000; Kaytor, 2004). Since both glutamine length 
and time are invariable in our experiments, we investigated whether overexpression of Pin1 
reduces formation of aggregates/insoluble complexes by affecting huntingtin intracellular 
concentration. Whole-cell lysates from co-transfected Hek293 cells were analyzed by 
immunoblot using MAB5490 antibody. As shown in figure 9e, the amount of mutant 
huntingtin was significantly reduced in cells co-expressing Pin1 compared to negative control. 
This result suggests that Pin1 activity on aggregation is exerted by lowering the concentration 
of huntingtin fragment. 
We then tested whether Pin1 effect on protein concentration is also exerted on wild-type 
huntingtin. We used a cDNA construct encoding for the first 171 aminoacids of huntingtin 
with 21 glutamines fused at the carboxy-terminus with the GFP (htt1-171Q21GFP). Typical 
results, reported in figure 10, indicate that Pin1 reduces wild-type huntingtin concentration 
compared to control. These data therefore suggest that Pin1 overexpression reduces huntingtin 
concentration irrespective of polyglutamine length. 
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Figure 10:  Huntingtin concentration is reduced by Pin1 irrespective of polyQ length. Hek293 cells were co-
transfected with htt1-171Q21GFP and HA-Pin1 or HA-Pin1DM. 48 hours after transfection cells were 
harvested and processed for western blot analysis. Blot was probed for huntingtin (MAB5490), β-
actin and Pin1 (α-HA). The picture is representative of at least 4 independent experiments. 
Pin1 effect is not exerted through direct interaction with huntingtin amino-
terminal fragment 
We have previously found that both endogenous full-length huntingtin and ectopically 
expressed amino-terminal huntingtin fragment, spanning the first 550 aminoacids of the 
protein (htt1-550), interact with Pin1 (unpublished results, PhD Thesis S. Michelazzi). On the 
contrary, the N-terminal fragment htt1-171Q60GFP, which contains a single Pin1 putative 
binding site (huntingtin S120-P), failed to interact with Pin1 in GST-Pin1 pull down 
experiments. Nonetheless, we decided to test whether Pin1 activity on huntingtin 
concentration was exerted by direct interaction with the fragment. Using site-directed 
mutagenesis we generated the mutant construct htt1-171Q60S120AGFP, where Serine 120 was 
replaced with Alanine (Fig. 11a). Hek293 cells were co-transfected with htt1-171Q60S120AGFP 
and HA-Pin1 or HA-Pin1DM as control. The proportion of inclusion-containing cells was 
evaluated by fluorescent microscopy forty-eight hours after transfection. As reported in figure 
11, the overexpression of htt1-171Q60S120AGFP and Pin1 did not result in the disappearance of 
intracellular inclusions (Fig. 11b). However, when we examined by filter trap and western blot 
analyses the expression of huntingtin we found that, both in SDS-insoluble and in total protein 
preparations, huntingtin concentration was reduced by Pin1 (Fig. 11c and d).  
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Figure 11:  The expression of htt1-171Q60S120AGFP mutant protein is also affected by Pin1. (a) Schematic 
representation of htt1-171Q60S120AGFP cDNA. The point mutation S120A was inserted by site-
directed mutagenesis. (b) Immunofluorescence images of Hek293 cells co-transfected with htt1-
171Q60S120AGFP and HA-Pin1 or HA-Pin1DM. Cells were fixed 48 hours after transfection and 
stained with anti-HA antibody. Scale bar 10 µm. (c) Filter trap assay shows that of htt1-
171Q60S120AGFP SDS-insoluble material in cells co-expressing HA-Pin1 is reduced compared to 
control HA-Pin1DM. Cells were processed 48 hours after transfection. (d) Western blot analysis of 
whole-cell lysates showing a slight reduction of htt fragment when co-expressed with HA-Pin1 
compared to control HA-Pin1DM. Blot was probed for huntingtin (MAB5490), β-actin and Pin1 (α-
HA). The pictures are representative of at least 4 independent experiments. 
These results are in agreement with those obtained using htt1-171Q60GFP fragment and 
therefore suggest that Pin1 effects are not exerted via a direct interaction. 
 
To further support this observation we have used a shorter mutant N-terminal huntingtin 
fragment, namely htt exon 1 (httex1Q60GFP), which does not contain the S120P site. Co-
expression experiments in Hek293 cells with httex1Q60GFP and either HA-Pin1 or HA-
Pin1DM showed the same reducing effect of Pin1 on the co-expressed shorter mutant 
huntingtin fusion protein (Fig. 12).  
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Figure 12:  Pin1 decreases httex1Q60GFP protein level. Western blot of Hek293 cells co-transfected with 
httex1Q60GFP and HA-Pin1 or HA-Pin1DM. Blot was probed for huntingtin (α-GFP), β-actin and 
Pin1 (α-HA). The picture is representative of 3 independent experiments. 
We then addressed whether Pin1 activity is specifically exerted on huntingtin fragments or if 
is a more general consequence of Pin1 overexpression. We used therefore a cDNA construct 
encoding for GFP that was co-transfected with Pin1 or with Pin1DM as control. Whole-cell 
lysates were prepared from transfected cells and analyzed by immunoblot with an anti-GFP 
antibody. The result shown in figure 13 indicates that GFP protein expression is not even 
slightly affected by Pin1, suggesting that Pin1 effect is not a general consequence of its 
overexpression. 
 
Figure 13:  GFP protein concentration is not altered by Pin1. Hek293 cells were co-transfected with GFP and HA-
Pin1 or HA-Pin1DM. 48 hours after transfection cells were harvested and processed for western blot. 
Blot was probed for GFP, β-actin and Pin1 (α-HA). The picture is representative of 3 independent 
experiments. 
Pin1 affects huntingtin half-life 
Reduced expression of huntingtin fragment may be due to enhanced protein degradation 
mediated by Pin1. To investigate this hypothesis we have evaluated the steady state level of 
huntingtin in presence of Pin1.  
Hek293 cells were co-transfected with htt1-171Q60GFP and HA-Pin1 or HA-Pin1DM as 
control, according to our standard transfection protocol. After six hours, cells were treated 
with 40µg/ml of cycloheximide (CHX) (time zero), an antibiotic which inhibits protein 
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translation by blocking the ribosome activity. Whole cell extracts were then prepared after 
different times from CHX treatment (2 and 4 hours) and analyzed by immunoblot (Fig. 14). 
The relative amount of huntingtin at different times was determined by densitometric scanning 
of western blot signal using β-actin for normalization. As shown in the representative 
experiment of figure 14 the relative half-life of huntingtin fragment after 2 hrs was reduced of 
~ 2.5 fold (ratio htt/β-actin signal = 0.4) in presence of Pin1, compared to a slight reduction of 
1.4 fold (ratio htt/β-actin signal = 0.7) with the control. Thus, these results demonstrate that 
Pin1 overexpression reduces protein half-life of huntingtin fragment.  
 
Figure 14:  Pin1 reduces huntingtin half-life. Hek293 cells were co-transfected with htt1-171Q60GFP and HA-Pin1 
or HA-Pin1DM as control. 6 hours after transfection cells were treated with 40 µg/ml CHX (time 
zero) for 2 or 4 hours. At the indicated time cells were harvested and analyzed by western blot. Blot 
was probed for huntingtin (MAB5490), β-actin and cyclinD1. The picture is representative of 4 
independent experiments. 
Pin1 has been reported to modulate transcriptional activity of RNA polymerase II (RNAP II) 
by influencing phosphorylation status of the C-terminal domain of the largest subunit. Pin1 
overexpression causes formation of a hyperphosphorylated inactive form of RNAP II and 
specifically inhibits transcription of mRNA precursors in vivo (Xu, 2003; Xu, 2007). We 
therefore evaluated whether transcription efficiency of the various constructs we had used, 
may be affected by Pin1. By RT-qPCR we measured mRNA expression of huntingtin (htt1-
171Q60GFP and htt1-171Q60S120AGFP) and GFP constructs in transfected cells overexpressing 
Pin1 or Pin1DM. As expected, a reduction in transcription efficiency was observed with Pin1, 
but not with its negative control. However, the extent of the reduction was identical for 
huntingtin and for GFP constructs (data not shown). 
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Pin1 stimulates activity of the UPS 
It is known that GFP is a highly stable protein which is not normally degraded by proteasome 
(Bence, 2001; Verhoef, 2002). Conversely, it has been reported that N-terminal fragments of 
huntingtin are proteasome substrates (Jana, 2001; Chandra, 2008). Since GFP protein levels 
were not altered by Pin1 overexpression (Fig. 14) we have hypothesized that Pin1 might 
reduce huntingtin half-life by a degradation mechanism that involves the proteasome. 
Before testing this hypothesis we assessed whether in our experimental conditions htt1-
171Q60GFP was a proteasome substrate. Hek293 cells were transfected with the huntingtin 
fragment and twenty-four hours later treated with the proteasome inhibitor MG132 (10µM), or 
with DMSO as control, for six hours. Whole-cell extracts were prepared and analyzed by 
western blot using MAB5490 antibody. As shown in figure 15 the huntingtin fragment 
accumulates upon proteasome block. We also noted an increase in cyclinD1 on MG-132 
treatment, consistent with inhibition of proteasome activity (data not shown). 
 
Figure 15:  Htt1-171Q60GFP is substrate of the proteasome. Hek293 cells were transfected with htt1-171Q60GFP. 24 
hours after transfection cells were treated with 10µM MG-132 or DMSO for 6 hours, then harvested 
and analyzed by Western blot. Blot was probed for huntingtin (MAB5490) and β-actin. 
To explore the effect of Pin1 overexpression on proteasome activity we used the YFPu reporter 
system (Bence, 2001; Bennett, 2005). YFPu is a protein containing a short degron (CL1), a 
signal for the ubiquitin-proteasome pathway, fused to the C-terminus of YFP (Bence, 2001). 
Since YFPu, conversely to YFP, is normally rapidly degraded by the proteasome (t1/2 ~30min), 
it represents an appropriate experimental system to test proteasome activity in the presence of 
Pin1. In our experimental settings, the YFPu was transfected at a very low concentration to 
avoid excessive protein accumulation due to overexpression. 
Hek293 cells were co-transfected with YFPu cDNA and with HA-Pin1 or HA-Pin1DM. Forty-
eight hours after transfection the level of YFPu protein was evaluated by immunofluorescence 
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and western blot of whole-cell lysates. As shown in figure 16, the YFPu signal was 
significantly reduced in cells co-expressing Pin1 compared to negative control both in 
immunofluorescence and in western blot analysis (Fig. 16a and b). 
 
Figure 16:  Pin1 promotes proteasome degradation of YFPu. Hek293 cells were transfected with YFPu or YFP as 
control and HA-Pin1 or HA-Pin1DM according to the standard protocol. 48 hours after transfection 
cells were harvested and subject to western blot or fixed in 4% PFA for IF analysis. (a) 
Immunofluorescence images of Hek293 co-expressing YFPu and HA-Pin1 or HA-Pin1DM. Cells 
were fixed 48 hours after transfection and stained with anti-HA antibody. Scale bar 10 µm. (b) 
Western blot of whole-cell lysates from Hek293 co-transfected with YFPu and HA-Pin1 or HA-
Pin1DM. Blot was probed for YFPu (α-GFP), β-actin and Pin1 (α-HA). (c) Western blot analysis of 
whole-cell lysates of Hek293 co-transfected with YFP and HA-Pin1 or HA-Pin1DM. Blot was probed 
for YFP (α-GFP), β-actin and Pin1 (α-HA). The pictures are representative of at least 4 independent 
experiments. 
The same experiment was repeated overexpressing YFP, which is not normally degraded by 
proteasome, with either HA-Pin1 or HA-Pin1DM. As shown in figure 16c the presence of 
Pin1 does not affect YFP concentration. These results, therefore suggest that Pin1-mediated-
degradation is occurring by proteasome activity. 
To exclude the possibility that transcription efficiency accounted for the differences in the 
expression level, we performed RT-qPCR using mRNA isolated from cells transfected with 
YFPu or YFP and either HA-Pin1 or HA-Pin1DM. In agreement with results obtained with 
GFP and huntingtin fragments, YFP mRNA level was significantly reduced (P<0.05) of ~30% 
by Pin1 (Fig. 17b). However, interestingly, mRNA level of YFPu was not reduced in presence 
of Pin1 (Fig. 17a). Since steady state level of YFPu protein is determined by a balance between 
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protein production and protein degradation, RT-qPCR data further support a role for Pin1 in 
inducing protein degradation by proteasome. 
 
Figure 17:  Pin1 reduces mRNA level of YFP but not of YFPu. Graphic representations of normalized mRNA 
expression values of Hek293 cells co-transfected with YFPu (a) or YFP (b) and either HA-Pin1 or 
HA-Pin1DM. 48 hours after transfection cells were harvested for RNA extraction. 1 µg of total RNA 
was retrotranscribed and analyzed by real time quantitative PCR. mRNA expression values were 
normalized against 18S RNA and β-actin mRNA values. Error bars represent SDs of 4 independent 
experiments. 
2.2.2 Characterization of htt1-171Q60S120AGFP 
The mutant huntingtin construct we have generated by site-directed mutagenesis (htt1-
171Q60S120AGFP), has attracted our attention for its ability to generate a large amount of 
inclusion when transfected in Hek293 cells. We have therefore further analyzed the property 
of this construct by direct comparison with wild-type htt1-171Q60GFP cDNA. 
The expression of the two cDNA constructs was first evaluated in a time course of 12 hours. 
Hek293 cells were transfected with htt1-171Q60S120AGFP or htt1-171Q60GFP cDNAs and 
whole-cell protein extracts were prepared at fixed time intervals of 3, 6, 9 and 12-hours after 
transfection. Western blot analysis revealed that the amount of mutant fragments was 
increased compared to wild-type, starting from 6 hour after transfection up to 12 hours (Fig. 
18). In addition, inspection by fluorescent analysis showed that htt1-171Q60S120AGFP fragment 
gave rise to inclusion formation already at 12 hours from transfection (data not shown). 
We have tested whether unequal transcription efficiency may provide an explanation for the 
expression level differences between the two constructs. By RT-qPCR transcript levels were 
found to be similar (data not shown). 
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Figure 18:  Protein expression of mutant S120A htt1-171 fragment is increased compared to wild-type. Hek293 
cells were transfected with htt1-171Q60GFP (WT) or htt1-171Q60S120AGFP (S120A) and collected at the 
indicated time after transfection for Western blot analysis. Blot was probed for huntingtin (MAB5490) 
and β-actin. 
Higher amount of mutant fragment might be related to its increased stability compared to 
wild-type. We measured therefore the half-life of the two huntingtin fragments by blocking 
protein synthesis with CHX. Hek293 cells were transfected with either htt1-171Q60GFP or htt1-
171Q60S120AGFP and six hours after transfection were treated with 40 µg/ml of CHX.  Whole-
cell extracts were prepared after different time from CHX treatment (2 and 4 hours) and 
analyzed by immunoblot with MAB5490 antibody. The relative amount of both huntingtin 
fragments was determined by densitometric scanning of western blot signal using β-actin for 
normalization. As shown in figure 19, htt1-171Q60GFP exhibited a t1/2 of ~2hrs, whereas that of 
htt1-171Q60S120AGFP was ~4hrs.  
Thus the substitution of Serine with Alanine at residue 120 of huntingtin leads to a mutant 
protein with a longer half life. 
 
Figure 19:  The point mutation S120A stabilizes htt1-171 fragment. Hek293 were transfected with htt1-171Q60GFP 
or htt1-171Q60S120AGFP and 6 hours after transfection were treated with 40 µg/ml CHX. Cells were 
collected at the indicated time points and processed for Western blot analysis. Blot was probed for 
huntingtin ( MAB5490) and β-actin. The picture is representative of 3 independent experiments. 
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2.2.3 To investigate Pin1 activity in regulating gene expression profiling in 
in vitro and in vivo model systems of HD 
Pin1 silencing in striatal cells 
We took advantage of a well established HD cellular model, represented by immortalized 
STHdh striatal cells derived from wild type and knock-in mouse striata, to set up Pin1 
silencing and subsequent gene expression profiling analysis. 
For the silencing of Pin1 we used Dharmacon SMARTpool siRNAs specifically designed to 
block Pin1 expression and Dharmacon RISC-free siRNA as control.  
HdhQ7/Q7 and HdhQ111/Q111 striatal cells were transfected with 75 nM of Pin1 SMARTpool (SP) 
or with RISC-free (RF) for 72 hours, and then collected for RNA extraction. Pin1 silencing 
was monitored both by western blot with anti-Pin1 antibody, and by real time quantitative 
PCR, as shown in figure 20. 
 
Figure 20:  Pin1 silencing in STHdh striatal cells. Cells were transfected with 75 nM Pin1 Smart pool (SP) or 
SiControl Risc Free (RF) and 72 hours later harvested for protein and RNA extraction. (a) Western 
blot analysis of Pin1 in STHdh striatal cells at 72 hour from transfection. Blot was probed for Pin1 and 
β-actin. (b) Pin1 mRNA level at 72 hours from transfection. The expression value was normalized 
against β-actin mRNA values (Normalized fold expression). Error bars represent SDs from 3 
independent experiments. 
Microarray analysis 
Three out of six independent silencing experiments were then chosen for further microarray 
analysis. Total RNAs were treated with DNAse and purified with the RNeasy Mini Kit from 
Qiagen. RNA quality was assessed using an Agilent 2001 Bioanalyzer and only samples with 
an RNA Integrity Number (R.I.N.) higher then 8 were then used. Five µg of total RNA from 
each sample were templates to generate biotinylated cRNA. They were then hybridized to the 
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Affymetrix murine 430A 2.0 gene chips that contain approximately 14,000 well-characterized 
mouse genes. After overnight hybridization, Chips were scanned and image files were 
processed. Data were then analyzed by using the R Bioconductor package (Gautier L 2004) 
The transient nature of Pin1 knock-down led to some variability among the replicates and 
reduced the number of differentially expressed genes. Nonetheless, statistical analysis using 
LIMMA on a subset of probes filtered for fold-change threshold of 1.5, returned 8 genes 
differentially expressed in striatal wild-type cells and 6 genes in mutant cells (Tab.6). 
Genes differentially expressed in silenced wild-type striatal cells 
Gene name 
Gene 
symbol FC 
secreted Ly6/Plaur domain containing 1 Slurp1 1.56 
ribonuclease, RNase A family, 1 (pancreatic) Rnase1 0.66 
Solute carrier family 25 (mitochondrial carrier; phosphate 
carrier), member 23 Slc25a23 0.65 
deiodinase, iodothyronine, type II DIO2 0.64 
glycerophosphodiester phosphodiesterase domain containing 2 Gdpd2 0.63 
synaptotagmin IX Syt9 0.56 
zinc finger protein 91 Zfp91 0.54 
protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 Pin1 0.46 
 
Genes differentially expressed in silenced mutant striatal cells 
Gene name 
Gene 
symbol FC 
DNA-damage-inducible transcript 4-like Ddit4l 1.66 
scavenger receptor class A, member 5 (putative) Scara5 1.65 
HECT, UBA and WWE domain containing 1 HUWE1 1.62 
Transformed mouse 3T3 cell double minute 2 MDM2 1.52 
Matrix metallopeptidase 9 Mmp9 0.61 
protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 Pin1 0.47 
Tab. 6:  Statistical analysis was performed by means of Linear Models for Microarray Data (LIMMA). All 
adjusted P-values are 0.05. FC= Fold change. 
In both experiments Pin1 was at the top of the list of down-regulated genes proving both the 
efficiency of the siRNA as well as the sensitivity of the array hybridizations. 
Interestingly, besides Pin1, no overlap was noted between the two gene lists suggesting 
specific effects of Pin1 silencing in a wild-type or mutant background.  
No Gene Ontology terms enrichment was observed in the list of the wild-type cells while 2 out 
of the 4 induced genes in mutant cells were E3 ubiquitin ligases: HUWE1 and MDM2. 
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We then arbitrarily choose these two as well as Ddit4l and Slc25a23 for validation with real-
time quantitative PCR.  
As shown in figure 22a, differential expression was confirmed for all the genes tested. 
Interestingly, Ddit4l and Slc25a23 expressions were altered in basal conditions (Fig 21b).  
Furthermore, HUWE1 and MDM2 mRNAs were induced only by Pin1 interference on mutant 
cells with an invariant gene levels in the two cell lines in untreated conditions (Fig.21a and b). 
 
Figure 21:  Expression analysis of Ddit4l, MDM-2, HUWE1 and Slc25a23 in STHdh striatal cells upon Pin1 
silencing (a) and in normal conditions (b). STHdh striatal cells were transfected with 75 nM Pin1 
Smart pool (SP) or 75nM SiControl Risc Free (RF) and 72 hours later harvested for RNA extraction. 1 
µg of total RNA was retrotranscribed and analyzed by real time quantitative PCR. mRNA expression 
levels were normalized relatively to β-actin mRNA level. Error bars represent SDs from 3 
independent experiments. 
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Gene expression profile of Hdh knock-in mice with a Pin1 knock-out 
background 
Generation of HdhQ7/Q111 : Pin1-/- mouse line 
To dissect the contribution of Pin1 to HD pathogenesis and/or progression, we generated a 
new mouse line by breeding HdhQ7/Q111mice with Pin1+/- mice. The F1 offspring was 
intercrossed in order to obtain the following littermates: HdhQ111/+:Pin1+/+, HdhQ111/+:Pin1-/-, 
Hdh+/+:Pin1+/+, Hdh+/+:Pin1-/-, HdhQ111/Q111:Pin1-/-, HdhQ111/Q111:Pin1+/+. The exact genotype of 
the mice was determined by PCR on DNA extracted from tail biopsy. 
Gene expression profile of HdhQ7/Q111:Pin -/- mouse striata 
To characterize this new mouse model, we have performed gene expression profiling 
experiments from the striatum of mice with different genotypes.  
Although the first robust gene expression alterations in the striatum of Hdh knock-in mouse 
occur at ~10 months of age, transcriptional dysregulation has been reported as early as 3 
weeks of age (Fossale, 2002; Chan, 2002; Woodman, 2007; Kuhn, 2007).  
Gene expression profiles of Pin1-/- mice have never been reported so far, nonetheless, evident 
neurodegeneration of the frontal cortex and spinal cord, with features resembling AD, was 
described to occur as early as six months of age, suggesting the existence of neuronal 
dysfunctions preceding the overt neuronal loss (Liou, 2002; Liou, 2003).  
Therefore, we decided to analyze mice at 15 weeks of age aiming to avoid the establishment 
of irreversible neuronal damages due to the loss of Pin1 activity.  
RNAs from the striata of three mice for each genotype were purified as described in Methods 
section. They were then hybridized separately to the very same Affymetrix murine 430A 2.0 
gene chips. Normalization, filtration and statistical analysis of the data files were performed as 
reported in Methods section. A false discovery rate of 10% was applied. 
First, we evaluated the effects of mutant huntingtin on a Pin1 wild-type background. The 
results are summarized in Table 7. 
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Genes differentially expressed in HdhQ7/Q111: Pin1+/+ mice 
Gene name Gene symbol FC 
Early growth response 2 Egr2 2.40 
FBJ osteosarcoma oncogene Fos 1.88 
tropomyosin 1, alpha Tpm1 1.68 
abhydrolase domain containing 1 Abhd1 1.65 
Rho guanine nucleotide exchange factor (GEF) 5 Arhgef5 1.41 
poliovirus receptor Pvr 1.39 
aspartyl aminopeptidase Dnpep 1.37 
Tumor necrosis factor receptor superfamily, member 25 Tnfrsf25 1.36 
zinc finger protein 207 Zfp207 1.36 
ankyrin 3, epithelial Ank3 1.35 
RIKEN cDNA 8030411F24 gene 8030411F24Rik 1.32 
class II transactivator Ciita 1.28 
SNAP-associated protein Snapap 0.73 
Ras interacting protein 1 Rasip1 0.71 
gamma-aminobutyric acid (GABA-A) receptor, subunit 
alpha 3 Gabra3 0.65 
lymphocyte antigen 6 complex, locus H Ly6h 0.62 
expressed sequence AI467657 AI467657 0.58 
Bcl2-associated X protein Bax 0.55 
expressed sequence AI467657 AI467657 0.48 
Protein arginine N-methyltransferase 1 Prmt1 0.44 
Tab. 7:  Statistical analysis was performed by means of the Significance Analysis of Microarrays (SAM). The 
False Discovery Rate (FDR) was estimated at 10%. FC= Fold Change. 
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Then, we assessed the effect of Pin1 knock-down on a wild-type huntingtin background. The 
list of genes differentially expressed is reported in Table 8. 
Genes differentially expressed in HdhQ7/Q7: Pin1-/- mice.  
Gene name Gene symbol FC 
X-linked lymphocyte-regulated 4B Xlr4b 5.09 
immunoglobulin kappa chain, constant region Igk-C 3.36 
neurogenic differentiation 6 Neurod6 3.36 
early growth response 2 Egr2 3.12 
C1q-like 3 C1ql3 2.66 
early growth response 2 Egr2 2.50 
C1q-like 3 C1ql3 2.50 
RNA-binding region (RNP1, RRM) containing 3 Rnpc3 2.41 
Homer homolog 1 (Drosophila) Homer1 2.36 
BRCA1/BRCA2-containing complex, subunit 3 Brcc3 2.33 
kit ligand Kitl 2.30 
cerebellin 1 precursor protein Cbln1 2.29 
Kruppel-like factor 10 Klf10 2.28 
heat shock protein 1B Hspa1b 2.27 
procollagen-proline, 2-oxoglutarate 4-dioxygenase 
(proline 4-hydroxylase), alpha 1 polypeptide P4ha1 2.23 
FBJ osteosarcoma oncogene Fos 2.22 
Protein tyrosine phosphatase, receptor type, J Ptprj 2.15 
microtubule-associated protein 2 Mtap2 2.15 
cytoplasmic polyadenylation element binding protein 4 Cpeb4 2.12 
Special AT-rich sequence binding protein 2 Satb2 2.11 
tetratricopeptide repeat domain 14 Ttc14 2.07 
integrin alpha V Itgav 2.05 
DnaJ (Hsp40) homolog, subfamily B, member 5 Dnajb5 2.04 
microtubule-associated protein 2 Mtap2 2.03 
gamma-aminobutyric acid (GABA-A) receptor, subunit 
beta 3 Gabrb3 2.02 
brain derived neurotrophic factor Bdnf 2.02 
ubiquitin protein ligase E3A Ube3a 2.02 
mitogen activated protein kinase 14 Mapk14 2.00 
zinc finger protein 451 Zfp451 2.00 
histone cluster 1, H4h Hist1h4h 0.48 
chemokine (C-C motif) ligand 21a Ccl21a 0.47 
ribosomal protein S4, Y-linked 2 Rps4y2 0.35 
plasma membrane associated protein, S3-12 S3-12 0.24 
protein (peptidyl-prolyl cis/trans isomerase) NIMA-
interacting 1 Pin1 0.02 
Tab. 8:  Statistical analysis was performed by means of the Significance Analysis of Microarrays (SAM). The 
False Discovery Rate (FDR) was estimated at 10%. FC= Fold Change. 
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Finally, we analyzed the consequence of Pin1 knock-down on a mutant huntingtin background 
(Tab. 9). 
Genes differentially expressed in HdhQ7/Q111: Pin1-/- mice.  
Gene name Gene symbol FC 
arginine vasopressin Avp 2.17 
zinc finger protein of the cerebellum 4 Zic4 1.72 
peroxisomal biogenesis factor 13 Pex13 1.46 
immunoglobulin (CD79A) binding protein 1 Igbp1 1.45 
RIKEN cDNA 2700078E11 gene 2700078E11Rik 1.45 
amylase 1, salivary Amy1 1.44 
mitochondrial ribosomal protein 63 Mrp63 1.42 
microsomal triglyceride transfer protein Mttp 1.42 
EGF-like repeats and discoidin I-like domains 3 Edil3 1.41 
t-complex-associated testis expressed 2 Tcte2 1.41 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4 Ddx4 1.37 
immunoglobulin (CD79A) binding protein 1 Igbp1 1.35 
RIKEN cDNA 4921524J17 gene 4921524J17Rik 1.34 
Tumor necrosis factor alpha induced protein 6 Tnfaip6 1.34 
BRCA1/BRCA2-containing complex, subunit 3 Brcc3 1.34 
small nuclear ribonucleoprotein D1 Snrpd1 1.33 
chemokine (C-C motif) ligand 25 Ccl25 1.31 
zinc finger protein 191 Zfp191 1.30 
Ly6/neurotoxin 1 Lynx1 1.27 
isoleucine-tRNA synthetase 2, mitochondrial Iars2 1.26 
Thymopoietin Tmpo 1.26 
ORM1-like 1 (S. cerevisiae) Ormdl1 1.24 
cell cycle associated protein 1 Caprin1 1.24 
SRY-box containing gene 7 Sox7 1.24 
ubiquitin-conjugating enzyme E2D 3 (UBC4/5 
homolog, yeast) Ube2d3 1.22 
RIKEN cDNA C330007P06 gene C330007P06Rik 1.22 
RIKEN cDNA 2700078E11 gene 2700078E11Rik 1.21 
ubiquitin-conjugating enzyme E2D 3 (UBC4/5 
homolog, yeast) Ube2d3 1.18 
protocadherin 21 Pcdh21 0.64 
Histone cluster 1, H4h Hist1h4h 0.57 
Protein (peptidyl-prolyl cis/trans isomerase) NIMA-
interacting 1 Pin1 0.02 
Tab. 9:  Statistical analysis was performed by means of the Significance Analysis of Microarrays (SAM). The 
False Discovery Rate (FDR) was estimated at 10%. FC= Fold change. 
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2.3 DISCUSSION  
2.3.1 To investigate Pin1 activity in modulating huntingtin half-life 
and aggregate formation 
Proteolytic cleavage of huntingtin generates toxic N-terminal fragments that are prone to 
misfold and aggregate. Although the toxicity of aggregates is controversial, increasing 
evidences suggest that intermediate oligomeric species, occurring during the aggregation 
process, are pathogenic (Sanchez, 2004; Schaffar, 2004). The identification of proteins or 
chemical compounds that control aggregation process, for instance by increasing degradation 
of toxic fragments, is of large interest in the field of neurodegenerative research.  
In this work we have investigated Pin1 as a possible modulator of aggregate formation and 
protein stability in HD. 
Using a cell culture model we found that overexpression of Pin1 remarkably decreases 
inclusions and SDS insoluble material formed by N-terminal huntingtin fragments with 
expanded polyglutamine tract. Consistent with a process that links accumulation of misfolded 
proteins with their rate of degradation, we found that reduced inclusion formation was 
associated to decreased half-life of wild-type and mutant huntingtin fragments. 
There are increasing evidences that Pin1-catalysed prolyl isomerization modulates the half-life 
of many of its targets by changing protein interaction, subcellular localization and 
ubiquitination. 
For example, Pin1 increases the protein half-life of p53 by inhibiting its binding to the Mdm2 
ubiquitin ligase, which regulates the degradation of p53 (Zacchi, 2002). With a different 
mechanism the interaction of Pin1 to c-Myc facilitates its dephosphorylation at Ser62 by 
PP2A, triggering a series of events that promote c-Myc turnover by the ubiquitin-proteasome 
pathway (Yeh, 2004). 
We have previously demonstrated that Pin1 interacts with full-length huntingtin (unpublished 
data, Ph.D. thesis by S. Michelazzi). The N-terminal huntingtin fragment we have used 
contains a single Ser-Pro motif (Ser120P) that if phosphorylated may be target of Pin1. We 
have therefore hypothesized that Pin1 interaction at Ser120-Pro could modulate huntingtin 
stability. 
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The mutant protein we have generated by replacing Serine 120 with Alanine (Ala120-Pro) 
exhibited a very high stability compared to wild type (Ser120-Pro). However, when tested in 
co-transfection, we found that its intracellular concentration was also decreased by Pin1 
overexpression. Similar results were obtained with a shorter huntingtin fragment (exon 1) that 
lacks of Pin1 sites. These data, combined to the failure of wild type Ser120-Pro to interact with 
Pin1 in GST pull down assay, suggest that Pin1-mediated activity on huntingtin half-life is not 
dependent to direct interaction, but it is exerted through the action of a cellular constituent that 
target huntingtin for degradation. 
Misfolded huntingtin fragments have been found to interact with heat-shock proteins (HSPs) 
such as Hsp40 and Hsp70 (Krobitsch, 2000; Wyttenbach, 2000). The interaction of HSPs with 
N-terminal huntingtin is likely to represent an attempt of the cell to refold the misfolded 
protein. In line with this idea several studies have shown that overexpression of HSPs 
suppresses aggregation of truncated polyQ-containing proteins (Wyttenbach, 2002; Hay, 2004; 
Kitamura, 2006). The yeast Hsp104 overexpression, for example, was found to rescue 
aggregate formation in yeast (Krobitsch, 2000), in Caenorhabditis elegans (Satyal, 2000), in 
transgenic mouse and mammalian cell model of HD (Carmichael 2000; Vacher 2005). Of 
interest, Hsp104 was found to interact with Ess1, the yeast orthologue of Pin1 (Ho, 2002). 
When chaperones cannot refold abnormal proteins correctly, then they promote their substrate 
ubiquitination, which direct them to proteasome for degradation. It is tempting to speculate 
that Pin1 interaction with yet unknown chaperone may modulate its activity promoting 
degradation of huntingtin fragments.  
The UPP (ubiquitin proteasome pathway) is a major intracellular pathway for degradation of 
proteins. The substrate is first marked for degradation by covalent linkage to ubiquitin via a 
mechanism that occurs through the action of three classes of enzymes termed E1, E2, and E3. 
Ubiquitinated proteins, after binding to the 19S regulatory particle of proteasome, are 
deubiquitinated, unfolded and then translocated into the 20S component for proteolysis. 
Degradation is mediated by specific proteases that digest proteins to short peptides, which are 
released by proteasome and then rapidly hydrolyzed to aminoacids by cytosolic or nuclear 
peptidases. 
The ubiquitin ligation step mediated by E3-ubiquitin ligase enzymes is centrally important in 
determining the selectivity of protein degradation.  
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So far, four different E2 and E3-ubiquitin ligases have been found to associate with huntingtin 
fragments and to be responsible for their ubiquitination and degradation by proteasome 
(Kalchman, 1996; Jana, 2005; Yang, 2006; Mishra, 2008a). Among them, CHIP has been 
shown to promote also degradation of other disease-proteins as mutant SOD1, Tau, α-
synuclein and different polyQ-containing peptides (Cardozo, 2003; Petrucelli, 2004; Shin, 
2005; Jana, 2005). Transient overexpression of CHIP increases ubiquitination and rate of 
degradation of target proteins. E6-AP was recently described to interacts with the soluble 
misfolded polyQ proteins and associate with their aggregates (Mishra, 2008a). E6-AP, also 
known as ube3a, promotes degradation of other substrates including p53 (Mishra, 2008b). 
HIP2 is a member of the E2 family, is highly expressed in brain and it was the first ubiquitin 
enzyme found to interact with huntingtin (Kalchman, 1996).  
We found that overexpression of Pin1 increases the rate of degradation of N-terminus 
huntingtin fragment. Although we do not know whether ubiquitination of huntingtin is 
increased in our system, we might hypothesize that Pin1 enhances the rate of degradation by 
increasing the activity of ubiquitin ligases. Interestingly, by inspection of primary sequence of 
CHIP, E6-AP and HIP2, several putative Pin1 binding sites are found. Further experiments are 
obviously required to prove this hypothesis. 
Neuronal accumulation of aggregated protein is a feature of many neurodegenerative disorders 
including Alzheimer’s disease (AD), Parkinson’s disease (PD), familial amyotrophic lateral 
sclerosis (FALS), Huntington’s disease (HD) and related polyglutamine (polyQ) expansion 
diseases.  
Pin1 dysfunction has been already linked to neurodegeneration. In AD brains, Pin1 regulate 
dephosphorylation and function of Tau and APP. Its depletion causes increased formation of 
neurofibrillary tangles and selectively elevates the production of insoluble Aβ42 (Pastorino, 
2006). In PD, Pin1 accumulates in the Lewy bodies and its overexpression enhances the 
protein half-life and insolubility of -synuclein (Ryo, 2006). In ALS, Pin1 colocalizes with 
spinal cord neuronal inclusions and its inhibition reduces glutamate-induced perikaryal 
accumulation of phosphorylated neurofilament-H in neurons (Kesavapany, 2007). 
Our in vitro data implicate Pin1 in the clearance of huntingtin fragments. It will be of interest 
to assess in vivo whether Pin1-mediated activity is as well involved in this mechanism.  In 
HdhQ111 knock-in mice (C57BL/6N background), intranuclear inclusions are detected in the 
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striatum of heterozygous at 6 months of age (Lloret, 2006).  We are planning to assess whether 
timing formation of SDS-insoluble material and/or intranuclear inclusions in HdhQ7/Q111: Pin1-
/-
 mice we have generated is anticipated compared to age-matched HdhQ7/Q111 mice, which 
express Pin1.  
The mutant N-terminal huntingtin fragment we have generated by replacing Serine 120 with 
Alanine (Ala120-Pro) exhibits very high stability and deserves therefore additional comments.  
In a recent work, Chandra and colleagues have described the pentapeptide motif (FQKLL) at 
positions 123-127 of huntingtin as a novel proteasomal degradation signal. The motif, if 
introduced as a 15mer peptide (RNSPEF123QKLL127GIAME) to a heterologous protein 
(YFP), targets the fusion protein for proteasome degradation. Disruption of the motif by 
alanine substitution at the hydrophobic residues increases the steady state level of the protein. 
The role of this motif is not yet known (Chandra, 2008).  The 15mer peptide used by Chandra 
is only three residues apart from the S120P site that we have mutated to generate the fragment 
(htt1-171Q60S120AGFP) with increased half-life. We may therefore hypothesize that Serine 120 
is also important in regulating the activity of the proteasomal degradation signal but its role 
require further study.  
2.3.2 To investigate Pin1 activity in regulating gene expression 
profiling in in vitro and in vivo model systems of HD 
 We have previously shown that huntingtin is interacting with Pin1 and that this interaction is 
increased by polyQ expansion. Importantly, endogenous Htt/Pin1 protein complex occurs in 
vivo in a genetically precise mouse model of the disease.  
We have also shown that Pin1 may have an effect on degradation of N-terminus huntingtin 
fragment and, consequently, aggregate formation, without requiring the establishment of a 
common protein complex. This is important since it suggests that Htt/Pin1 interplay may occur 
at multiple levels intersecting multiple intracellular pathways. 
The intrinsic nature of the biochemical activity of Pin1 on substrate proteins makes this 
molecule an ideal drug target. Therefore, understanding the functional significance of Htt/Pin1 
interplay is of crucial importance. 
To this purpose, we have undertaken a genomic approach.  
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The analysis of gene expression profiles in neurodegenerative diseases has been a powerful 
tool to characterize metabolic and tissue dysfunctions in cellular and animal models of the 
diseases as well as in human post mortem brains.  
While the studies in humans suffer from the analysis of the final stage of a disease that has 
lasted many years, arrays data in cell culture and mouse models have provided unexpected 
insights on the neurodegenerative process. Among others, the analysis of gene expression in a 
mouse model of HD has identified for the first time an altered cholesterol metabolism that has 
then been confirmed in human subjects (Sipione, 2002).  Furthermore, transcriptome data 
from the striata of a genetically precise mouse model of the disease has pointed to an altered 
expression of Rrs1 as the earliest event so far identified in a still asymptomatic animal 
(Fossale, 2002).  
Diverse changes in gene expression may then be correlated in space and time to 
neuropathological landmarks of disease progression like striatal-specific nuclear accumulation 
of mutant huntingtin, aggregate formation and, ultimately, to behavioral deficits.  
Here we have taken advantage of a widely accepted in vitro cellular model system as well as 
of a genetically precise HD mouse. To eliminate Pin1 expression in these experimental 
settings we have transiently interfered Pin1 mRNA in vitro and bred HD mice with a Pin1 
knockout mouse line in vivo. 
To study gene expression changes we have used the affymetrix platform and analyzed data 
with the R Bioconductor package.   
Data analysis of in vitro Pin1 silencing 
First we discuss the in vitro data. 
Striatal cells represent a suitable cellular model to explore biochemical pathways involving 
mutant huntingtin and to test hypothesis on the HD-trigger mechanism. 
We performed Pin1 silencing in striatal cells and compared the gene expression profiles of 
mutant striatal cells to wild-type in order to identify differences that could account for Pin1 
knock-down in a mutant huntingtin-dependent way. 
As expected, the transient nature of the silencing delivery resulted in a considerable variability 
in the expression profiles of the replicates, reducing the number of genes differently expressed 
in a significant manner to a very few probes.  
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Indeed, we have found 12 genes which expressions were consistently altered in the 
experiments. We have validated four of them by real time PCR. As shown in Fig. 14a, 
differential expression was confirmed for all genes. Interestingly, the qPCR revealed that the 
down-regulation of Slc25a23 mRNA mediated by Pin1 silencing occurs in both cell lines. This 
effect was not detected in the microarray experiments since Slc25a23 gene was highly down-
regulated in mutant striatal cells in basal conditions. Being the level of Slc25a23 mRNA 
extremely low in mutant cells, a further down-regulation of about ~1.2 fold might be under the 
threshold of detection.  
We were thus confident that our gene expression analysis of transient interference was 
successful. 
Here we discuss some examples of interesting patterns of expression that involve intriguing 
genes. 
1. DNA-damage inducible transcript 4-like (Ddit4l) was strongly up-regulated in mutant cells 
versus wild-type in basal conditions. Pin1 silencing increased its expression in mutant cells 
only. 
This pattern of expression is interesting since it depends on the expanded polyQ tract both in 
untransfected striatal cells as well as when Pin1 is silenced. Furthermore, the biology of Ddit4l 
is intriguing. This gene encodes for a protein shown to be a potent negative regulator of 
mTOR (Corradetti, 2005). It acts downstream to AKT and upstream of TSC2 in coupling with 
another related protein named Redd1. It has been shown that a variety of stressors causes a 
rapid and stable increase in Ddit4l (Redd2) to reduce translation through mTOR inhibition 
(Corradetti, 2004; Proud, 2004). Depending on the cellular context, Ddit4l expression has been 
considered pro- or anti-apoptosis.  Importantly, its biological function may be related to the 
induction of autophagy, a cellular phenomenon central in HD pathogenesis. If so, Pin1 action 
may be interpreted as inhibiting autophagic activity. Further studies are needed to unveil 
Ddit4l potential role in HD and the regulatory function by Pin1. 
2. Genes that are not differentially expressed in untreated cells but strongly up-regulated by 
Pin1 siRNA in mutant cells only. 
This class of genes is the only one that seems to contain enriched Gene Ontology terms: 
transformed mouse 3T3 cell double minute 2 (MDM2) and HECT, UBA and WWE containing 
1 (HUWE1) are in fact E3 Ubiquitin Ligases. 
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MDM2 is an E3 ubiquitin ligase that, together with the p300 ‘‘transcriptional co-activator’’ 
protein (in its capacity as an E4 ligase), mediates the ubiquitination and proteasome-dependent 
degradation of the p53 tumor suppressor protein and other growth regulatory proteins 
(reviewed in Meek and Knippschild, 2003). The transcription of the MDM2 oncogene is 
induced by p53 after DNA damage, and the MDM2 protein then binds to p53 promoting its 
degradation. These two proteins thus form an autoregulatory feedback loop in which p53 
positively regulates MDM2 levels and MDM2 negatively regulates p53 levels and activity 
(Freedman, 1999). 
Pin1 is one of the most important regulators of p53 activity. It specifically binds 
phosphorylated p53 inducing p53 dissociation from MDM2 and its stabilization, which results 
in increased transactivation (Zacchi, 2002).  
Interestingly, it has been previously shown that mutant striatal cells present a higher level of 
stabilized p53 (Trettel, 2000). Therefore, the induction of MDM2 mRNA consequent to Pin1 
silencing may suggest a potential down-regulation of p53 in mutant cells, which does not 
occur in wild-type cells with basal levels of p53.  
It is extremely provocative that a second E3 ubiquitin ligase induced by siPin1 is HECT, UBA 
and WWE containing 1 (HUWE1), a central player in p53-dependent effects on cell cycle. In 
p53 wild-type cells, HUWE1 directly binds and ubiquitinates p53 and inactivation of 
endogenous HUWE1 is crucial for ARF-mediated p53 stabilization (Chen, 2005).  
It seems therefore reasonable that the main effect of Pin1 lack of activity in mutant cells may 
be related to p53 stabilization.  
It will be then important monitoring p53 levels after Pin1 siRNA transfections.  
Furthermore, it will be interesting to investigate whether MDM2 and HUWE1 might bind 
mutant huntingtin and promote its degradation. 
Gene expression profile of HdhQ7/Q111: Pin1-/- mouse striata 
The generation of a new transgenic mouse model harboring the HD mutation in absence of a 
functional Pin1 gene represented the first step in the dissection of a possible role for Pin1 in 
HD pathogenesis. 
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Hdh knock-in mice, designed to recapitulate more precisely the genetic lesion in human HD, 
were bred with Pin1-/- mice in order to obtain the new strain, double knockin-knockout, 
HdhQ7/Q111: Pin1-/-.  
Three list of genes resulted by our experiments: 
 
1. Genes induced in the HdhQ7/Q111 mutant mice include immediate early genes (Egr2 and 
Fos), while genes down-regulated surprisingly include a pro-apoptotic factor (Bax) and a 
GABA receptor subunit (Gabra3). 
Egr2 has been most widely studied in the context of the nervous system, and its targeting in 
knock-out mice results in early lethality concurrent to defects in hindbrain patterning, 
peripheral nerve myelination, and bone formation (Gillian, 2004). 
It is noteworthy that the altered expression of Egr2 gene has been widely related to HD 
pathology even if with opposing results (Chan, 2005; Kuhn, 2007). Egr2 was indeed found 
down-regulated in transgenic mice expressing short N-terminal mutant huntingtin fragment 
(R6/2 and N171Q82 mice) (Luthi-Carter, 2000; Chan, 2002; Kuhn, 2007), whereas it is 
overexpressed in mouse model expressing longer mutant huntingtin fragment (HD46, they 
express an N-terminal fragment of huntingtin encompassing the first 550 aa) or the full-length 
protein (YAC72) (Chan, 2002, Kuhn, 2007). 
c-Fos is a cellular proto-oncogene that dimerizes with a member of the Jun family to make an 
AP-1 transcription factor that binds to the AP-1-binding sites of DNA (Karin 1995). Pin1 has 
been shown playing a key role in regulating c-Fos activity (Monje, 2005). Interestingly, c-Fos 
has been related to HD as a down-regulated gene in some transgenic mouse models (R6/2 and 
N171-82Q) (Chan, 2002; Kuhn, 2007). 
 
2. Genes induced in Pin1-/- mice on a wild-type huntingtin background suggest a clear 
alteration of pathways involved in neuronal networks differentiation and maintenance: among 
them Homer1, Map2, BDNF and Neurod6.  
Homer1 is a constituent of the post-synaptic density structure and is involved in receptor 
cluster formation (Ango, 2002; Brandstatter, 2004). Its transgenic expression in the striatum 
has provoked an altered motor function as well a modified response to amphetamine (Tappe 
and Kuner, 2006). Homer1 up-regulation is concurrent to the induction of Map2, a well known 
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marker and organizer of dendritic structures. Furthermore, BDNF induction is also observed. 
This result is of great importance since down-regulation of BDNF has been linked to 
neurodegeneration in HD (Zuccato, 2003). Among the transcription factors, it is of special 
relevance the induction of Neurod6, a well know regulator of neuronal development and 
axonal pathfinding (Uittenbogaard and Chiaramello, 2004).  
The E3 ubiquitin ligase ube3a (E6-AP) is responsible for the Angelman syndrome, a genetic 
disorder with motor impairment and seizure. Importantly, ube3a was recently shown to 
ubiquitinate and induce degradation of huntingtin (Mishra, 2008a).   
3. The list of genes differentially regulated in Pin1-/- mice in a mutant huntingtin genetic 
background is particularly interesting.  
First, no common altered genes between HdhQ7/Q111 and HdhQ7/Q111: Pin1-/- mice are evident at 
this stage. 
This is important since it may suggest that the functional interplay between lack of Pin1 
expression and mutant huntingtin may lead to the establishment of an unexpected phenotype.  
The most differentially expressed gene was arginine vasopressin (AVP), a neuropeptide that 
acts as an endocrine and paracrine regulator of important systemic functions, namely, 
vasoconstriction, gluconeogenesis, corticosteroidogenesis, and excretion of water and urea. 
Although AVP fibers can be found throughout the CNS, expression of the AVP genes occurs 
almost exclusively in the hypothalamus (Fields, 2003). 
Most importantly, this gene has been found down-regulated in a mouse model of HD (Chan, 
2005). In this case, lack of Pin1 expression may reestablish physiological AVP level.   
We also noticed the altered expression of the immunoglobulin binding protein 1 (Igbp1) and 
of the DEAD box polypeptide 4 (ddx4).  
Immunoglobulin binding protein 1 (Igbp1) is a regulatory subunit of protein phosphatase 2A 
(PP2A) sustaining mTOR signaling and acting as a positive feedback mechanism on 
translation initiation (Kong, 2004).  
The Vasa DEAD-box helicases are widespread markers of germ cells across species and are 
involved in translational control. 
Some observations may be discussed on the biological meaning of these gene lists.  
We have monitored gene expression in the striatum of mice at 15 weeks of age with the intend 
to detect early events in HD pathogenesis and to avoid, at the same time, confounding effect 
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due to neurodegeneration associated with the loss of Pin1. In Pin1-/- mice, indeed, the first 
evidence of neuronal loss is detected later at six months of age and with features resembling 
AD (Liou, 2002; Liou, 2003). 
Clearly, gene expression analysis must be integrated with the classical phenotype description 
in HD and AD mouse models of the disease. This analysis has just started since it will require 
some time: mice will be analyzed by immunofluorescence to monitor some of the 
hystopathological and biochemical landmark of the neurodegenerative process including 
mutant huntingtin shuttling into the nucleus, intranuclear inclusion formation, BDNF 
transcription as well as behavioral tests. Attention will be also devoted to markers of neuronal 
dysfunction that have been previously described in Pin -/- mice during aging mimicking an 
AD-like phenotype. This analysis will be complemented with a series of new gene expression 
arrays at different times up to 2 years of age. 
This work is instrumental in answering the fundamental question concerning a potential 
protective or toxic effect of the lack of Pin1 expression in HD.  
No apparent behavioral abnormalities have been so far observed in the double mutant mouse 
model suggesting that lack of Pin1 does not strongly modify the polyQ-dependent 
neurodegenerative process.  
It is however clear that double mutant mice do not resemble the expression of the HD model 
or of the Pin1 KO at the same age. This is important since it may suggest that a 
pharmacological intervention on Pin1 activity may modify disease progression. 
Unfortunately there are some considerations we need to make for assessing the value of these 
data. 
First, we decided to consider each hybridization a biological replica consisting of a single 
animal. Therefore, we avoided multi-animal RNA pooling. This approach is very powerful, 
although it needs a higher number of replicas to consider an appropriate number of genes as 
statistically significant. The physiological range of intra-individual variation in the striatum of 
a 3 months old animal is difficult to judge and has potentially large effects on decreasing the 
number of genes that can make the threshold.  
We are now hybridizing a higher number of mice to increase the statistical significance of 
some differentially expressed genes. 
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We also believe that having a homozygous mouse for mutant huntingtin will accelerate 
neuropathogenesis and will render clearer some differential patterns of expression. We are 
now collecting three individual striata for each genetic repertory with homozygous mutant 
huntingtin.  
 
We are thus addressing this important question by increasing the number of mice, by 
analyzing mutant huntingtin in homozygosity and by following the double mutant mice 
throughout their lifespan. These in vivo experiments will provide a definitive answer on 
mutant Htt/Pin1 functional interplay. 
 
In this context, as preliminary information, we looked at those genes that did not pass the 
significance test, but showed an opposite sign of differential expression with respect to the two 
background situations. It may be of high biological relevance that some genes are common 
members of the differentially expressed gene lists but in a discordant direction (Tab. 10). It 
will be thus worth investigating whether this pattern of expression means that huntingtin and 
Pin1 act on the same pathway and/or whether lack of Pin1 may induce a partial reversal of the 
mutant htt-induced phenotype.  
 
 
Gene 
HdhQ7/Q111: Pin1+/+ 
Vs 
HdhQ7/Q7: Pin1+/+ 
HdhQ7/Q111: Pin1-/- 
Vs 
HdhQ7/Q111: Pin1+/+ 
HdhQ7/Q7: Pin1-/- 
Vs 
HdhQ7/Q7: Pin1+/+ 
Egr2 2.40* 0.63 2.50* 
c-Fos 1.88* 0.61 2.22* 
Avp 0.19 2.17* 0.73 
Cbln1 0.76 2.56 2.29* 
Tab. 10:  Fold change of Egr2, c-Fos, Avp and Cbln1 are indicated for the different genotypes. *statistically 
significant fold change values. 
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2.4 MATERIALS AND METHODS 
Plasmids and mutagenesis 
Httex1Q60GFP in pcDNA3.0 (Invitrogen), encoding the first exon (1-85 aa) of human 
huntingtin with 60 glutamines in frame with the N-terminus of GFP, was constructed by 
cloning PCR amplified Htt exon1 into EcoRI-XhoI sites of pcDNA3.0GFP vector. The GFP 
moiety was recovered by XhoI digestion from pGreenLantern-1 (GIBCO-BRL). Htt1-
171Q21/Q60GFP, encoding the N-terminal 171 amino acids of human huntingtin, with 21 and 
60 glutamines, was constructed by subcloning the NcoI-XhoI fragment of Htt cDNA into 
pcDNA3.0GFP vector. The point mutant htt1-171Q60S120AGFP was obtained by site 
directed mutagenesis using the two primer sets: 5’-ACCGGAATTCACCATGGCGACCCT 
GGAAAAGCTGA-3’, 5’-CTGAAATTCTGGGGCATTTCTGACAGA-3’, and 5’-TCTGT 
CAGAAATGCCCCAGAATTTCAG-3’, 5’-GTCATTTGCAAAATTGCCAAAAGAAGC 
CA-3’ and subcloned into the same pcDNA3.0GFP vector. 
HA-Pin1, encoding the human HA tagged Pin1 in pcDNA3.0 vector, was kindly provided by 
Prof. G. Del Sal (LNCIB);  
HA-Pin1 DM, encoding the human HA tagged Pin1 containing the point mutations Y23A 
S67E, was constructed by site directed mutagenesis using as template HA-Pin1Y23A, kindly 
provided by Prof. Del Sal G. (LNCIB) and the two primer sets: 5’-ACGAGGATCC 
GCGGACGAGGAG-3’, 5’-TGGGCCGCCGTTCCTGGCTGTG-3’, and 5’-CACAGCCAG 
GAACGGCGGCCCT-3’, 5’-ATCCACTCGAGTCACTCAGTGCGGAGG-3’, subsequently 
cloned into pcDNA3.0-HA.  
pEGFP-C2 (Clontech Lab., Palo Alto, CA, USA). pEYFPu was kindly provided by Prof. 
Poletti (University of Milan, Italy); pEYFP was derived by pEYFPu after elimination of the 
CL1 degron by XhoI-BamHI digestion. 
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Cell cultures 
STHdh striatal progenitor cell lines derived from wild-type (STHdhQ7/7), homozygous 
(STHdhQ111/111) and heterozygous (STHdhQ7/111) knock-in Hdh littermate mice embryos (E14 
striatal primordial), were cultured at 33ºC in D-MEM (Dulbecco’s modified Eagle’s medium), 
10% FBS (fetal bovine serum), 100 U/ml penicillin, 100 g/ml streptomycin, 400 g/ml G418 
for selection. The cells are immortalized with a Temperature Sensitive version of the SV40 
Large T-Antigen, which allows the cells to proliferate at the permissive temperature of 33ºC 
(Trettel, 2000). 
 
HEK293T (human embryonic kidney) cells were cultured at 37ºC in D-MEM (Dulbecco’s 
modified Eagle’s medium), 10% FBS (fetal bovine serum), 100 U/ml penicillin, 100 g/ml 
streptomycin. 
Transfection 
Lipofectamine 
Hek293T cells were transfected accordingly to the Lipofectamine 2000 (Invitrogen) protocol. 
Briefly, cells were plated in growth medium without antibiotics in 35mm cell culture dishes 
the day before transfection. 90% confluent cells were transfected using a total of 4 g DNA 
and 10 l Lipofectamine and medium was changed 7 hours after transfection. Cells were 
harvested and assayed 48 hours after transfection. 
Treatments 
Cycloheximide (CHX): transfected Hek293T cells were treated with 40 µM CHX (Sigma) for 
2 to 4 hours. 
MG-132 : transfected Hek293T cells were treated with 10µM MG-132 (MG-132) (Sigma) for 
6hours. 
 
 65 
Protein extraction, western blot and filter trap assay 
Western Blot  
Cells were washed in PBS, harvested in cold PBS and resuspended in different lyses buffers. 
For whole-cell lysates, the entire cell pellet was resuspended in 10% SDS, sonicated for 1 
minute and heated for 10 minutes at 95°C. Protein concentration was determined by 
Bicinconic Acid (BCA) (Sigma) assay using a calibration curve built with standard amounts of 
BSA (bovine serum albumin). 
To test Pin1 silencing, transfected cells were resuspended in Tris-Triton buffer (50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.2 mM EDTA, 1% Triton X-100, 10% Glycerol, protease 
inhibitors), incubated 20 minutes in cold room rocking and centrifuged at 13,000 rpm for 15 
minutes at 4°C. Protein concentration was determined by Bradford assay (Sigma). 
3-10 µg of protein lysates were mixed with 4X SDS sample buffer, boiled for 5 minutes and 
separated by SDS-PAGE electrophoresis. Proteins were then blotted at 100 V for 1 hour onto 
nitrocellulose transfer membrane (Schleicher & Schuell 0.2 µm). 
Membranes were blocked in 5% dried milk – Tris Buffer Saline (TBS)-0.1% Tween-20 (TBS-
T) for 1 hour at RT and then were incubated with the primary antibody, diluted in TBST-milk, 
with agitation. Blots were then washed three times with TBST and then incubated for 1 hour 
with secondary HRP conjugated antibody, diluted in TBST-milk, at RT. 
Protein bands were detected by HRP/hydrogen peroxide catalyzed oxidation of luminol by an 
enhanced chemiluminescence system (ECL western blotting detection reagents, Amersham 
Biosciences).  
Filter Trap Assay 
For the filter trap assay soluble/insoluble fractionation, cell pellets were resuspended in buffer 
1 (0.15 M sucrose, 15 mM HEPES (pH 7.9), 60 mM KCl, 15 mM NaCl, 5 mM EDTA, 1 mM 
EGTA) and cleared by centrifugation at 2,000 g for 10 minutes at 4°C. The obtained pellets, 
containing nuclei, mitochondria, ER and membranes, were resuspended in buffer 2 (10 mM 
HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KC1, 5 mM EDTA, 1 mM EGTA and 12.5% 
Glycerol) and centrifuged at 4,000 g for 15 minutes at 4°C. The remaining pellets  were 
 66 
resuspended in buffer 3 (0.05 M HEPES (pH 7.9), 0.75 mM MgCl2, 0.5 mM EDTA, 0.42 M 
KC1, 0.1 mM EGTA and 12.5% Glycerol), incubated for 20 minutes in cold room rocking and 
then spun down at 13,000 rpm for 15 minutes at 4°C.. The final pellet was sonicated and 
heated at 95°C in a 10% SDS solution to reach maximal resuspension. The obtained insoluble 
fraction was diluted to 0.2% SDS and 50 mM DTT before filtration. Approximately 10-30 µg 
of proteins were subjected to filtration through 0.22-µm cellulose acetate membrane 
(Schleicher & Schuell), the filters were fixed in 0.5% glutaraldehyde solution for 15 min and 
then treated as western blot. 
Immunofluorescence 
Cells were seeded onto 13 mm coverslips and allowed to attach for 24 hours before 
transfection. 48h after transfection cells were washed in PBS and fixed in 4% 
paraformaldehyde for 15 minutes at RT. After fixation, cells were rinsed in PBS and incubated 
5 minutes with glycine 100 mM to quench autofluorescence. Membrane permeabilization was 
performed using 0.1% Triton X-100. Cells were then incubated in BSA 1% for 30 minutes to 
block non specific sites before primary antibody incubation. 
Both primary and secondary antibodies were incubated in 1% BSA, 1% NGS. 
After primary antibody incubation, cells were washed twice in PBS and subjected to 
secondary antibody incubation. Nuclei were labeled using DAPI. Cells were washed twice in 
PBS and mounted on slides using Vectashield mounting medium. 
Images were captured with a Leyca confocal microscope by using a 40X oil objective. 
Antibodies 
The following primary antibodies were used: Mouse monoclonal anti-huntingtin (MAB5490, 
Chemicon, WB dilution 1:2.500); Mouse monoclonal anti-Pin1 (Santa Cruz Biotechnology, 
sc-46660, WB dilution 1:1.000); Chicken monoclonal anti-GFP (Aves Labs, Tigard, OR, 
GFP-1020, WB dilution 1:5.000); Mouse monoclonal anti--actin (Sigma, A1978, Saint 
Louis, MI, WB dilution 1:5.000); Mouse monoclonal anti-HA tag (kindly provided by Dr. L. 
Collavin, LNCIB, WB dilution 1:1000, IF dilution 1:100). 
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The following HRP secondary antibodies were used: HRP conjugated goat anti-mouse 
antibody (DAKO, WB dilution 1:1.000); HRP conjugated goat anti-chicken antibody (DAKO, 
WB dilution 1:2.000). 
The following secondary antibodies were used for IF: Alexa-594 donkey anti-mouse (1:1000). 
Pin1 silencing by RNAi in striatal cells 
Striatal cells were transfected according to Dharmafect 1 protocol (Invitrogen) with 75 nM 
Pin1siGENOME SMART pool (M-040655-00-0020, Mouse PIN1, NM_023371, Dharmacon), 
or with non-targeting siRNA with impaired ability for RISC (RNA-induced silencing 
complex) interaction as negative control, siCONTROL RISC-Free siRNA (D-001220-01-20 
Dharmacon). After 72 hours cells were collected by trypsine treatment. 1/10 of total cell 
suspension volume was used for WB analysis, the rest was centrifuged at 900 rpm for 5 
minutes, washed in PBS and centrifuged again. The cell pellet was resuspended in 1 ml of 
TRIZOL and stored at -80°C for subsequent RNA extraction. 
HdhQ111/Q111 – Pin1-/- mice 
To place the HdhQ111 allele on the Pin1-deficient background HdhQ111/+:Pin1+/- mice, generated 
by crossing HdhQ111/+ and Pin1+/- mice, both on C57Black/6N background, were intercrossed 
to give HdhQ111/+:Pin1+/+, HdhQ111/+:Pin1-/-, Hdh+/+:Pin1+/+, Hdh+/+:Pin1-/-, HdhQ111/Q111:Pin1-/-, 
HdhQ111/Q111:Pin1+/+ littermates. 
Genotyping 
DNA was prepared from tail biopsy. CAG repeats were sized by PCR in GB buffer (66 mM 
Tris-HCl (pH 8.8), 16 mM (NH4)2SO4, 2 mM MgCl2, 0.7% b-Mercaptoethanol), 0.01 mg/ml 
BSA, 10% DMSO, 200µM dNTPs, 0.5µM primers with 0.4 U/µl RedTaq. Cycling condition 
were 90”@ 94°C, 35 X (30”@94°C, 30”@ 56/65°C, 90”@ 72°C), 10'@ 72°C. PCR products 
were resolved in 1% agarose gel. Primer sets were as follow: wild type 5'-
CCTGGAAAAGCTGATGAAGG -3', 5'- TGGACAGGGAACAGTGTTGC-3'; knock-in 5'-
ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC-3', 5'-GGCGGCTGAGGAAGCTGA 
GGA-3'.  
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Pin1 genotype was determined by PCR using RedTaq (Sigma). Cycling conditions were 3'@ 
94°C, 35 X (30”@94°C, 30”@ 60/64°C, 90”@ 72°C), 10'@ 72°C. PCR products were 
resolved in 1% agarose gel. Primer sets were as follow: wild type 5'-AGCACCCGATCCT 
GTTCTGCAA-3', 5'-AAGGGATTAGAAGCAAGATTCG-3'; knockout 5'-AGCACCCGA 
TCCTGTTCTGCAA-3', 5'-CAGAGGCCACTTGTGTA-3'.Genotyping of all animals was 
confirmed after dissection. 
Mouse brain dissections 
HdhQ7/7-Pin1 wt,  HdhQ7/7-Pin1 KO, HdhQ7/111-Pin1 wt and HdhQ7/111-Pin1 KO mice were used 
for microarray analysis. 
Mice at 15 weeks of age were euthanized by CO2 exposure following the CCM regulations and 
the brains were dissected into striatum, cortex and cerebellum, immediately frozen in liquid 
nitrogen, and stored at -80°C. 
RNA preparation, analysis and Microarray 
RNA extraction  
Cells were washed in RT 1X PBS, then harvested with trypsine and homogenized in cold 
TRIZOL; mouse striata were homogenized in cold TRIZOL. 
Total RNA was isolated with TRIZOL reagent (Invitrogen/Life Technologies, Carlsbad, CA) 
according to manufacturer’s instructions, quantified spectrophotometrically at 260 nm using 
NanoDrop ND-1000 (Thermo Scientific, Wilmington, DE, USA), and analyzed using the 
RNA nanochip method on a Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).Total 
RNA was pretreated with DNase I using a DNA-free kit (Ambion Inc., Austin, TX, USA) and 
additionally purified over RNeasy Columns (Qiagen, Valencia, CA, USA). 
RT-qPCR 
Six different silencing experiments were settled, the best three were chosen for successive 
microarray analysis. 
RT reactions were performed in 20 µl with 1 µg of DNase-treated total RNA, 1X reaction mix, 
and 1 µl of Reverse Transcriptase (Bio-rad, iSriptTM cDNA synthesis kit). Reaction conditions 
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were 5 min at 25°C, 50 min at 42°C and 5 min at 85°C. Quantitative PCR reactions were 
performed with a BioRad iCycler iQ instrument (Bio-Rad Laboratories, Foster City, CA, 
USA), using the iQ Custom SYBR- Green Supermix (Bio-Rad, Foster City, CA, USA). PCR 
reactions were performed in 25 µl reaction volumes containing 1 µl of cDNA, 250 nM of each 
primer and 1X reaction mix. Each cDNA was run in duplicate for the target and the 
normalizing gene (β-actin and/or 18S) in the same 96-well plate for all samples. Cycle 
parameters were 3 min at 95°C (10 s at 95°C, 20 s at 56°C  and 30 s at 72°C) for 40 cycles. To 
quantify the mRNA levels for each sample and primer set, a standard curve was generated 
with known dilutions of total cDNA. The relative value for each unknown sample was then 
calculated from its respective standard curve using linear regression analysis. To normalize the 
differences in the amount of total RNA added to each reaction, we used β-actin as endogenous 
control. The normalized expression value was then calculated by dividing the relative 
quantitation value of each sample and primer set by the relative quantitation value of β-actin. 
Specificity of amplicon was determined by melt curve analysis and gel electrophoresis. 
Primers were designed using Beacon Design 5.0 software (Premier Biosoft International, Palo 
Alto, CA, USA). The following primer pairs were used for pin1 analysis: murine Pin1 
(GenBank accession n° NM_023371), 5'-CCAGAAGATTAAGTCAGGAGAGGAAG-3', 5'-
CCGTAGAGCAAACGACGCATCCTC-3'; murine β-actin (GenBank accession n° 
NM_007393), 5'-TGAAATAAGTGGTTACAGGAAGTC-3', 5'-GCAGTACATAATTTACA 
CAGAAGC-3' (TIB MOLBIOL, Genova, Italy). 
Primer sequences for significative genes obtained from silenced cells were as follow: MDM2 
(GenBank accession n° NM_010786), 5'-GCAAGCACCTCACAGATTCCAG-3', 5'-GCTGC 
TGCTTCTCGTCATATAACC-3'; HUWE1 (GenBank accession n° NM_021523), 5'-AGTGG 
TGCTGGCAGTCCTTAAC-3', 5'-GTCAGTAGCGGAGTCCTCTTGTC-3'; Ddit4l (GenBank 
accession n° NM_030143), 5'-AGAGTTGTTGGACGGTGGCTATC-3', 5'-GGGACCAAGA 
CCTTAGAGCAACC-3'; Slc25a23 (GenBank accession n° NM_025877), 5'-TTGGCAGGAA 
TGGCGAGACC-3', 5'-AACTCATCAGGCACCGTCA GG-3'; murine β-actin as above. 
To measure mRNA level of overexpressed constructs, the following primer sets were used: 
human huntingtin (GenBank accession n° NM_002111), 5'-CTACCAAGAAAGACCGTGTG 
AATC-3', 5'-CCACCATCCTGACATCTGACTC-3'; htt1-171GFP, 5'-AGTGCTTTTCCAGA 
TACCCAGAC-3', 5'-TCCTTAAAGTCAATGCCCTTCAAC-3'; EGFP (Clontech, GenBank 
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accession n° U55763), 5'-GCCCGACAACCACTACCTGAG-3', 5'- CGGCGGTCACGAA 
CTCCAG-3'; human β-actin (GenBank accession n° NM_001101), 5'- CGCCGCCAGCTC 
ACCATG-3', 5'-CACGATGGAGGGGAAGACGG-3'; 18S RNA, 5'- CGTCTGCCCTATC 
AACTTTCG-3', 5'-GCCTGCTGCCTTCCTTGG-3'. YFP and YFPu mRNAs were amplified 
using EGFP primers. 
Microarray: probe preparation and hybridization 
RNAs for microarray analysis fulfilled the following quality control criteria: R.I.N. > 8.0 and 
28S/18S ratio ~2, which were calculated by Bioanalyzer. Approximately 5 µg of total RNA 
was processed to produce biotinylated cRNA targets. cDNA synthesis was performed with 
GeneChip® One-Cycle cDNA Synthesis Kit (Affymetrix, Santa Clara, CA, USA; cod. n° 
900431). Double-strand cDNA containing the T7 promoter sequence was used as a template 
for in vitro transcription (IVT), amplification and biotin-labeling to prepare cRNA 
(Affymetrix, cod. n° 900449). Each synthesis step was followed by a purification one with the 
GeneChip® Cleanup Module (Affymetrix, cod. n° 900371), the same kit was also used for the 
fragmentation of the cRNA probes. Probes were hybridized on the GeneChip® Mouse 
Genome 430A 2.0 Array (Affimetrix, cod. n° 900498), a single array representing 
approximately 14,000 well-characterized mouse genes. 
Microarrays: data analysis 
After hybridization, Affymetrix GeneChip Mouse Genome 430A 2.0 Arrays were scanned and 
image data was saved as .dat files. Cell intensity data was computed from the image data using 
the Affymetrix GeneChip Operating Software (GCOS), and saved as .cel files. Further data 
processing was performed with R and BioConductor, while statistical analysis was performed 
with the MultiExperiment Viewer, as detailed below. 
.cel files were imported in the R environment for statistical computing and graphics 
(http://www.r-project.org/) using the “affy” package from the BioConductor software project 
(http://www.bioconductor.org/). Quality assessment of the data was performed with the “affy” 
and “affyPLM” packages. Data was then processed using the “rma” function from the “affy” 
package. “rma” (Robust Multi-Array Average) yields probe expression measure by a 
combination of background adjustment, data normalization and summarization of probe 
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effects (Irizarry et al., 2003). Normalized data was then filtered according to the Affymetrix 
detection call, so that only probes that had a “Present” call in at least one of the arrays were 
retained (McClintick and Edenberg, 2006).  
Statistical analysis of silenced striatal cells was performed by means of LIMMA (Linear 
Models for Microarray Data) (Smyth, 2004) as implemented in the “limma” package in 
BioConductor. The statistical test was applied to the subsets of probes showing a fold change 
of at least 1.5. P-values were adjusted for multiple testing using Benjiamini and Hochberg’s 
method (Benjiamini and Hochberg, 1995). 
Statistical analysis of mouse striata data was instead performed with the MultiExperiment 
Viewer (MeV) software (Saeed et al., 2003) using the SAM module (Significance Analysis of 
Microarrays; Tusher et al., 2001, implemented as in Chu et al., 2002). A False Discovery Rate 
(FDR) of 10% was applied to detect significant differentially expressed genes. 
Statistical analysis 
Statistical analysis was Student’s t-test, choosing P<0.05 as significant. Weighted means were 
calculated for data produced in replica experiments. Calculated means and standard deviations 
were plotted using the graph tool of Microsoft Excel. 
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CHAPTER 3: RRS1 AND ER STRESS IN HUNTINGTON’S 
DISEASE 
3.1 INTRODUCTION  
The elongated polyglutamine tract of mutant huntingtin causes the protein to acquire a new 
property that is particularly deleterious to the medium-sized spiny neurons of the striatum. 
Onset of clinical symptoms in HD patients precedes death of about 16 years and typically 
occurs when an estimated ~30% of neurons are lost and the remaining ones are sickened 
(Vonsattel, 1985). Correlation studies between CAG repeat number and severity of pathology 
in HD brains suggest that the initial trigger may occur early in life, possibly at birth. The 
description of these initial molecular events is crucial to design therapeutic intervention for the 
cure of the disorder. 
In HdhQ111 knock-in mice, a presymptomatic genetic model of the disease, the first phenotypic 
change is observed at 10 weeks of age when mutant huntingtin accumulates in the nucleus of 
medium-spiny neurons (Wheeler, 2000). Under the hypothesis that this early phenotype is 
associated with altered gene expression, Fossale and colleagues have screened for genes 
conserved in evolution, which are likely to encode for essential proteins (Fossale, 2002). 
Total RNA extracted from striatum of homozygous HdhQ111 mice was hybridized to 
Research Genetics Human GENEFILTERS. The microarray analysis revealed a single human 
cDNA, Rrs1 (Regulator of Ribosome Synthesis; GenBank accession n°. NM_015169) that 
was found upregulated in homozygous HdhQ111 mice. By quantitative real time PCR they also 
demonstrated that Rrs1 mRNA regulation fulfils the HD criteria of dominance, striatal 
specificity and polyglutamine-dependence. Rrs1 mRNA was indeed found increased both in 
homozygous and heterozygous HdhQ111 striatum at different ages. At 5 months of age, 
increased Rrs1 mRNA was also found in homozygous mutant cortex and cerebellum although 
no significant change was detected in same brain regions from HdhQ111 heterozygous mice. 
Thus in contrast to striatum, a single copy of mutant huntingtin was not sufficient to yield 
increased Rrs1 mRNA in these brain regions at a young age, indicating that the underlying 
process exhibits striatal specificity. 
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Moreover, a significant increase of Rrs1 mRNA was found in striatum of other lines of Hdh 
CAG knock-in mice (HdhQ50 and HdhQ92), consistent with a molecular phenotype that reflects 
a dominant polyQ-dependent mechanism (Fossale, 2002). 
Most importantly, Rrs1 mRNA expression was also found increased of about 2.4 fold in HD 
postmortem brain compared to age matched control indicating that the expression of this gene 
is increased as a consequence of mutant huntingtin in human disease. 
 
Rrs1, first studied in Saccharomyces cerevisiae, encodes for a nucleolar protein essential for 
ribosome biogenesis (Tsuno, 2000). The biogenesis of ribosomes requires many trans-acting 
factors to process and modify the primary pre-5S and polycistronic 35S transcripts into mature 
small subunit (18S) and large subunit (5S, 5.8S and 25/28S) rRNAs. Once assembled the two 
ribosomal subunits are released from the nucleus and exported to the cytoplasm. 
Rrs1 was found to be a member of the yeast Ribosome and rRNA Biosynthesis (RRB) regulon 
(Wade, 2001) that is a transcriptionally co-regulated set of genes that are required for 
ribosome biosynthesis. Its depletion in Saccharomyces cerevisiae causes defects in the 
maturation of 25S rRNA and in the assembly and nuclear export of the 60S ribosomal subunit 
(Tsuno, 2000; Miyoshi, 2004). Recently, Rrs1 was found to be a component of the pre-
ribosomal subcomplex which also includes RpL11, RpL5, Rpf2 and 5S rRNA (Miyoshi, 2002; 
Nariai, 2005; Zhang, 2007). Preribosomes lacking the constituents of the Rrs1 neighborhood 
are largely intact, but they cannot undergo further maturation, are prematurely released to the 
nucleoplasm and cannot be exported to the cytoplasm (Zhang, 2007). 
It is known that in yeast the alteration of the secretory pathway, from the insertion of the 
nascent peptide into the endoplasmic reticulum (ER) to the formation of the plasma 
membrane, prevents the continued synthesis of the components of the ribosomes, causing the 
repression of both ribosomal protein genes and rRNA genes (Mizuta and Warner, 1994). Of 
interest, in Saccharomyce cerevisiae Rrs1 was reported to be one of the gene essential for the 
transcriptional repression of rRNA and ribosomal protein genes in response to a secretory 
defect (Tsuno, 2000). 
The impact of polyQ expansions on ribosome synthesis and assembly is currently unknown. 
Furthermore, the interplay between mutant huntingtin, the integrity of the secretory pathways 
and ribosome biogenesis remains to be elucidated.  
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Here we report that mammalian Rrs1 is localized both in the ER and in the nucleolus. This 
subcellular distribution is shared with its newly discovered binding partner Lyric. 
Furthermore, Rrs1 and Lyric are components of the ER stress response in neurons. We then 
show that ER stress is an early presymptomatic event in the striatum of an HD mouse model. 
PREFACE 
Rrs1 expression in mammalian cells has been studied in a collaborative effort between our 
laboratory and the laboratory directed by Marcy MacDonald (MGH, Boston).  
Unless otherwise specified, all the data reported here arise from my own experiments and data 
analysis. 
3.2 RESULTS 
Detection of Rrs1 in mammalian cells 
Rrs1 has been studied so far only in yeast and no literature data are available on Rrs1 protein 
in mammalian cells.  To investigate the role of Rrs1 in HD, Elisa Fossale (MGH, Boston) 
developed a rabbit polyclonal antiserum, named FUN1, raised against the N-terminal region 
(1-194 aa) of the mouse Rrs1 protein. The antibody was tested by western blot for its ability to 
reveal endogenous or ectopically expressed Rrs1 protein in mammalian cells. A band of ~40 
kDa, which corresponds to the predicted molecular weight of mouse/human Rrs1, was 
specifically detected (Fig. 1a).  
The intracellular localization of endogenous Rrs1 was studied in STHdhQ7/Q7 cells by 
immunoflorescence. Confocal analysis revealed a nucleolar distribution of Rrs1 protein, which 
was found to co-localize with the nucleolar marker fibrillarin (Fig. 1c). Interestingly, Rrs1 
staining was also observed in the cytoplasm, with a distribution pattern reminiscent of a 
protein associated with the membrane compartment. 
Then cellular lysates from STHdhQ7/Q7 striatal cells were separated into Triton X-100 soluble 
(supernatant SN) and insoluble (pellet P) fractions to investigate the partition of Rrs1 protein 
between these two cellular components. As shown in figure 1b Rrs1 was detected both in SN 
fraction, which contains soluble proteins, and in the P fraction, which contains insoluble and 
membrane-associated proteins. 
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These data prove that mammalian Rrs1 is localized in the nucleolus and in the cytoplasm 
probably associated to the membrane compartment. 
 
 
Figure 1:  First characterization of Rrs1 in mammalian cells. (a) Wild-type striatal cells (STHdhQ7/Q7) were 
transfected with Rrs1 and, after 48 hours, both transfected (Rrs1) and untransfected (UN) cells were 
lysed and subjected to WB with anti-Rrs1antibody. Anti-Rrs1 antibody specifically recognizes both 
overexpressed and endogenous Rrs1. (b) WB analysis of Triton-X100 soluble (supernatant SN) and 
insoluble (pellet P) fractions from STHdhQ7/Q7 striatal cells. Rrs1 is localized in both fractions, with a 
higher concentration in the pellet. (c) Immunofluorescence of Rrs1 in wild-type STHdhQ7/Q7 striatal 
cells and its colocalization with fibrillarin, a marker for nucleoli. Rrs1 shows also a cytoplasmatic 
staining. Experiments were performed by E. Fossale. 
A yeast two-hybrid screening to identify Rrs1 interactors 
To gain a better understanding of the cellular function of Rrs1, Silvia Michelazzi (SISSA) 
performed a yeast two-hybrid screening to identify Rrs1 binding proteins. Mouse full-length 
Rrs1 was used as bait to screen a human fetal brain cDNA library. As expected, some of the 
interactors are proteins involved in ribosome biogenesis (GRSF1, GNL2, C2f, RPL18A, 
TSR1). Interestingly, we also found proteins that participate in different biological activities 
including splicing (C1QBP, SFRS11), transcription (YBX1, zfp690), response to unfolded 
protein (Hsp90A), and nucleus-cytoplasm transport (KPNA2). Finally, among the stronger 
Rrs1 interactors, was found the protein Lyric/3D3.  
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Lyric/3D3, also known as Methaderin and Astrocyte Elevated gene-1 (AEG-1), is a protein 
highly conserved in mammals with no homologues in nonvertebrate species. Lyric is a novel 
transmembrane protein of the ER and nuclear envelop and it colocalizes with fibrillarin in the 
dense fibrillar component (DFC) compartment of the nucleolus. Since the DFC compartment 
of the nucleolus is the site of rRNA transcription, early posttranscriptional rRNA processing 
events and ribosomal assembly, Lyric has been suggested to coordinate ER function with 
protein production at the site of ribosome biosynthesis, in response to ER stress (Sutherland, 
2006). 
Rrs1 and Lyric co-immunoprecipitate in mammalian cells 
The interaction between Rrs1 and Lyric was validated by co-immunoprecipitation 
experiments, using cell line ectopically expressing both Rrs1 and Lyric. Hek293 cells were co-
transfected with either Rrs1 and Lyric HA-tagged cDNAs or Rrs1 and an empty HA vector 
(pcDNA3.0HA) as control. Forty eight hours after transfection protein extracts were 
immunoprecipitated with the polyclonal anti-HA antibody and analyzed by western blot with 
anti-Rrs1 antiserum (FUN1). As shown in figure 3, Rrs1 was specifically co-
immunoprecipitated with Lyric. We could not perform the reverse co-immunoprecipitation 
given the inability of FUN1 to immunoprecipitate Rrs1. 
 
Figure 2:  Rrs1 is co-immunoprecipitated by Lyric. HEK293 cells were co-transfected with Rrs1 and HA-lyric 
or pcDNA3.0-HA, as negative control, and cell lysates were incubated with anti-HA antibody. 
Immunoblot analysis was performed with FUN1 anti-Rrs1 and anti-lyric antibody. 
Subcellular localization of Rrs1 and Lyric in striatal cells 
The subcellular localization of Lyric in STHdhQ7Q/7 striatal cells was detected by 
immunofluorescence with anti-Lyric/3D3 antibody (SS), kindly provided by Dr. Sutherland 
(Fig. 3a). As expected, Lyric staining was observed both in the nucleoli and linked to ER 
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(Southerland, 2006). Interestingly, the fluorescent pattern of Lyric strongly resembles Rrs1 
(Fig. 3b). 
 
Figure 3:  Immunofluorescence of Lyric (a) and Rrs1 (b) in wild-type striatal cells. Experiment performed by E. 
Fossale. 
We have therefore investigated whether the cytoplasmic component of Rrs1, observed by 
immunofluorescence, is associated to the ER. Confocal analysis was performed in STHdhQ7Q/7 
striatal cells by costaining of Rrs1 with the integral ER protein calnexin. As shown in figure 4, 
Rrs1 was found to co-localize with the marker calnexin to the ER compartment.  
 
Figure 4:  Immunofluorescence of Rrs1 in STHdhQ7/Q7 striatal cells and its colocalization with the ER marker 
calnexin.  
Rrs1 mRNA expression is induced by ER stress  
The ER fulfils many functions and it is known to be extremely sensitive to alteration of the 
cellular homeostasis. When stressed the ER sends signals to the cytoplasm and to the nucleus 
promoting compensative responses that include, among others, the inhibition of protein 
synthesis exerted through the control of translation and ribosome biogenesis (Sun, 2002). 
In yeast Rrs1 expression was found to be essential in repressing ribosome synthesis in 
response to a defect in the secretory pathway (Tsuno, 2000). In mammals Rrs1 localizes both 
in the nucleolus and in the ER membranes as its partner Lyric. Therefore we investigated 
whether these two proteins are involved in the neuronal response to ER stress. 
 96 
STHdhQ7/Q7 striatal cells were treated at different times (3, 6 and 12 hours) with Tunicamycin, 
a well-known inductor of ER stress. Total RNA was extracted and expression of Rrs1 and 
Lyric were measured by RT-qPCR both in Tunicamycin and in control DMSO-treated cells. 
As shown in figure 5a, a significant progressive induction of Rrs1 mRNA level was observed 
starting from 6 hrs up to 12 hrs of treatment. Interestingly, Lyric mRNA was also induced 
although with a slower kinetics. As shown in figure 5b a significant up-regulation of Lyric 
mRNA was indeed reached only after 12 hours of tunicamycin treatment suggesting that Lyric 
might be a component of the later phase of the response.  
 
Figure 5:  Kinetics of Rrs1, Lyric, BiP, CHOP and Herpud1 mRNAs with persistent ER stress in wild-type 
striatal cells. STHdhQ7/Q7 striatal cells were treated with 1µg/ml tunicamycin for the indicated hours 
and harvested for RNA extraction. mRNA expression level was measured by RT-qPCR and 
normalized relatively to β-actin mRNA level. (a) Rrs1, (b) Lyric, (c) BiP, CHOP and Herpud1 
normalized mRNA levels. Error bars represent SDs from five independent experiments. **P<0.005; 
***P<0.0005. 
We also measured, as control, the expression of BiP, CHOP and Herpud1, which are known 
markers of the ER-stress response (Li, 1994; Wang, 1996). As expected mRNA level of these 
genes is specifically induced after treatment in our experimental conditions (Fig. 5c). 
These data prove for the first time that Rrs1 and Lyric are components of the ER stress 
response in mammalian cells.  
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Rrs1 and Lyric mRNA expression in STHdhQ111 striatal cells  
Fossale and collaborators have shown that mutant huntingtin increases Rrs1 mRNA 
expression both in HD postmortem brains and in HdhQ111 knock-in mice. 
Here we have extended the analysis to ST HdhQ111/ Q111 cells. 
By quantitative real time PCR we have compared Rrs1 mRNA levels in wild-type (STHdhQ7/ 
Q7) and homozygous mutant (STHdhQ111/Q111) striatal cells. Conversely to data obtained with 
human postmortem brain and with mouse striatum we could not detect differences in Rrs1 
expression in the proliferating striatal cells (Fig. 6). 
Interestingly, as reported in figure 6 Lyric mRNA showed a significant increase of expression 
(P<0.0005) in STHdhQ111/Q111 cells.  
 
Figure 6:  Expression of Rrs1 and Lyric mRNA levels in STHdh striatal cells. Equal expression level is found 
for Rrs1 mRNA, whereas Lyric mRNA is significantly upregulated in STHdhQ111/Q111 striatal cells 
with respect to wild-type. Error bars represent SDs from seven independent experiments. 
***P<0.0005.  
Although STHdhQ111/Q111 cells present abnormal ER compartment (Trettel, 2000), no literature 
data are available on presence of an ER stress response in this cell line.  
Therefore, by RT-qPCR we compared the endogenous levels of BiP, CHOP and Herpud1 in 
wild-type and homozygous mutant striatal cells. As shown in figure 7, similarly to Rrs1, no 
difference in BiP mRNA expression was revealed between wild type and mutant cells. In 
addition, we found that Herpud1 mRNA was significantly decreased in STHdhQ111/Q111 cell, 
whereas the level of CHOP mRNA was significantly increased. Although these observations 
support an ongoing stress response (induction of CHOP), proliferating STHdhQ111/Q111 cells do 
not seem to exhibit the canonical features of a cellular ER stress response. They may present 
alternative compensative mechanisms for the altered cellular homeostasis triggered by mutant 
huntingtin. 
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Figure 7:  BiP, CHOP and Herpud1 expression in STHdh striatal cells. mRNA levels were measured by RT-
qPCR and normalized relatively to β-actin mRNA level. STHdh striatal cells show no difference in the 
expression level of BiP mRNA, whereas both CHOP and Herpud1 mRNAs are differentially 
expressed in STHdhQ111/Q111 striatal cells with respect to wild-type. Error bars represent SDs from five 
independent experiments. ***P<0.001. 
We then monitored wild-type and mutant striatal cells ability to respond to ER stress inducers. 
By quantitative real time PCR, mRNA levels of Rrs1, BiP, CHOP and Herpud1 were 
measured after tunicamycin treatment. Surprisingly, we observed higher induction of Rrs1, 
BiP, CHOP and Herpud1 in STHdhQ7/Q7 cells compared to mutant (1.6, 26, 41, 25 fold in 
STHdhQ7/Q7 versus 1.5, 22, 31, 18 fold in STHdhQ111/Q111 respectively). 
These data may suggest the existence of compensative mechanisms in mutant cells that 
counteract ER stress including an altered basal level of expression of CHOP and Herpud 
mRNAs. 
Increased expression of ER stress-related mRNA markers in HdhQ111 striatum 
Our findings with tunicamycin treatment in STHdhQ7/7 cells indicate that Rrs1 expression is 
induced by ER-stress. We have therefore hypothesized that in HdhQ111 knock-in mice the 
increased expression of Rrs1 mRNA may represent an early response to a perturbation of the 
ER homeostasis triggered by mutant huntingtin.  
To test this hypothesis we have first replicated in our experimental environment the 
quantitative analysis of Rrs1 mRNA expression in striatum of mutant and wild-type mice. 
Total RNA was isolated from five mouse striata of each genotype at different ages (3 months 
and 1 year) and analyzed by RT-qPCR. The results reported in Figure 8a show that Rrs1 was 
significantly increased of ~2.3-fold (P<0.001) in heterozygous HdhQ111 striatum compared to 
wild-type striatum at 3 months of age. Furthermore, assays of Rrs1 mRNA in homozygous 
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HdhQ111 and wild-type striatum at 1 year revealed a ~2-fold (P<0.02) increase in the mutant 
striatum, indicating an ongoing impact of mutant huntingtin on Rrs1 mRNA expression (Fig. 
8b). 
 
Figure 8:  Rrs1 mRNA phenotype in  HdhQ111 striatum. Quantitative real-time PCR assays were performed with 
RNA isolated from striata dissected from HdhQ111 mice at 3 months (a) and 1 year (b) of age. (a) 
Rrs1/β-actin mRNA ratios for mutant HdhQ111 heterozygous striatum plotted as a histogram, showing 
a significant 2.3-fold increase, compared with levels of Rrs1 mRNA in wild-type striatum. Bars 
indicate standard deviation. ***P<0.001. (b) The histogram displays Rrs1/β-actin striatal mRNA 
ratios determined for wild-type and HdhQ111 homozygotes, showing a significant 2.0-fold increase of 
Rrs1 mRNA. Bars indicate standard deviation. **P<0.01. 
To determine whether Lyric mRNA was also increased as a consequence of HD CAG repeat 
expansions, we performed RT–qPCR assays to assess striata from HdhQ111 mice. As shown in 
Figure 9, four out of five heterozygous HdhQ111 mice show a significant increase of Lyric 
mRNA compared to wild-type mice.  
 
Figure 9:  Lyric mRNA expression in Hdh mouse striata is affected by mutant huntingtin. Quantitative real-time 
PCR assays were performed with RNA isolated from four striata dissected from HdhQ111 heterozygous 
mice and four wild-type control littermates at 3 months of age. Lyric/β-actin mRNA ratio show a 
nearly significant 1.3 fold increase of Lyric mRNA compared with levels in wild-type striatum. Bars 
indicate SDs.  
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No significant variation was instead observed at 1 year of age (data not shown). 
To evaluate whether ER-stress may account for Rrs1 up-regulation in striatum of knock-in 
mice, we performed RT-qPCR assays for BiP, CHOP and Herpud1 from single mouse striata. 
The results reported in figure 10a show a significant up-regulation of the chaperones BiP and 
Herpud1, as well as of CHOP mRNAs in heterozygous HdhQ111striata compared to wild type 
at three months of age. Consistent with a progressive dysregulation of many cellular processes 
at 1 year of age homozygous knock-in mice still show increased expression of Bip and 
Herpud1 mRNAs, whereas the difference in the level of CHOP mRNA was no longer 
detectable (Fig 10b). 
These data prove for the first time the existence of an ER stress response as an early event in 
HD pathogenesis. 
 
Figure 10:  BiP, CHOP and Herpud1 mRNA expression in Hdh mouse striata. Normalized mRNA levels were 
measured by RT-qPCR and are shown relative to β-actin mRNA level. (a) HdhQ111 heterozygous 
knock-in mice show a significative difference in the expression level of BiP, CHOP and Herpud1 
mRNAs at 3 months of age of 1.3, 1.2 and 1.4 fold, respectively. Error bars represent SDs. (b) 
HdhQ111 homozygous knock-in mice show persistent higher mRNA levels of BiP and Herpud1 also at 
1 year of age, whereas the mRNA level of CHOP are unchanged. Error bars represent SDs. Six mice 
for each genotype were used. *P<0.05; **P<0.01; ***P<0.0005. 
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3.3 DISCUSSION 
In this work we have described for the first time Rrs1 expression in mammalian cells.  
Using a specific antibody that we have generated, we have found that Rrs1 is a protein of ~ 40 
kDa that localizes in the nucleoli, as previously observed in yeast (Tsuno et al., 2000), and in 
the cytoplasm.  
In the nucleolus Rrs1 colocalizes with fibrillarin that is a marker of the dense fibrillar 
component (DFC) of the nucleoli, which contains actively transcribing rRNA genes along 
with nascent rRNA transcripts and is the site of maturation of pre-rRNA transcripts. These 
data are in full agreement with Rrs1 expression and function in yeast, where it was found to be 
a member of the yeast Ribosome and rRNA Biosynthesis (RRB) regulon (Wade, 2001), a 
transcriptionally co-regulated set of genes that are required for ribosome biosynthesis. 
Here we report for the first time that mammalian Rrs1 is also located in the ER. 
By scanning Rrs1 primary sequence, two consensus for ER membrane localization are found 
both at its N- and C-terminals, XXRR (EGQR) and KKXX (GKRR), providing molecular 
mechanisms for its subcellular distribution.  
In order to gain a better understanding of the cellular function of Rrs1 we performed a yeast 
two-hybrid screening with a human fetal brain library to identify Rrs1-interacting proteins.  
Among the 12 Rrs1-interacting proteins expressed in the nervous system, we isolated proteins 
located in both ER and nucleolus (Lyric/3D3) as well as involved in ribosome biogenesis 
(GRSF1, GNL2, C2f, RPL18A, TSR1), splicing (C1QBP, SFRS11), transcription (YBX1, 
zfp690), response to unfolded protein (Hsp90A) and in the nucleus-cytoplasm transport 
(KPNA2).  
Since Rrs1 and Lyric share their subcellular distribution we focused our attention on this new 
interactor. Lyric was previously identified as a human immunodeficiency virus-1 inducible 
and tumor necrosis factor-α-inducible transcript in primary human fetal astrocytes. Its 
expression is elevated in >95% of human malignant glioma. Furthermore, it downregulates the 
expression of the glutamate transporter EAAT2, a protein implicated in glutamate-induced 
excitotoxicity (Kang, 2005). 
For its dual localization it has been suggested to play a role in coordinating the activities of the 
ER and nucleolus (Sutherland, 2006). 
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In eukaryotic cells, the ER is the primary organelle in the secretory pathway where proteins 
are synthesized, folded and post-translational modified prior to be delivered to other secretory 
compartments. In addition, the ER is also the place where intracellular Ca2+ is stored and 
where lipids and sterols are synthesized. 
The ER is extremely sensitive to alteration of homeostasis that disrupts its functions. When the 
load of unfolded proteins stored in the ER reaches a threshold, an imbalance occurs, called 
“ER stress”. Cells respond to ER stress by activation of the unfolded protein response (UPR) 
pathways where signal are transduced from the ER to the cytoplasm and to the nucleus to 
induce the expression of genes encoding mediators of host defense. This response changes the 
expression of specific chaperones, enhances degradation of misfolded protein and inhibits 
protein synthesis to decrease the load within the ER (Rao, 2004). Protein synthesis is mainly 
controlled by a translational attenuation mechanism, which entails the phosphorylation of 
eIF2α by PERK with consequent inhibition of cap-dependent translation (Harding, 1999). A 
concurrent mechanism of control is mediated by IRE1β protein, which, in response to ER 
stress, cleaves rRNA to attenuate translation (Iwawaki, 2001). When ER homeostasis cannot 
be restored, prolonged UPR may induce apoptosis (Breckenridge, 2003). 
Increasing evidences connect ER compartment with huntingtin activities. By a variety of 
methods several investigators have reported huntingtin to target ER membranes and to be 
essential for normal ER structure (Omi, 2005). The first 18 amino acids of huntingtin have 
been found to contain a membrane-targeting domain that mediates the association of the 
protein with the ER. The disruption of this domain or the induction of ER stress causes 
huntingtin to be actively transported into the nucleus via an active process, which involves the 
residues 81–588 of the protein. Notably, increased nuclear entry of mutant huntingtin due to 
loss of ER-targeting results in increased toxicity (Atwal, 2007). 
Alteration of ER homeostasis is becoming increasingly important in understanding the 
pathology of several protein-misfolding neurodegenerative diseases, including Parkinson’s 
and Alzheimer’s diseases (Lindholm, 2006). 
In the present work we found that Rrs1 and its protein interactor Lyric are components of the 
neuronal stress response. Furthermore, that early dysregulation of Rrs1 and Lyric mRNAs 
expression in mutant HdhQ7/Q111 heterozygous mice is concomitant to clear evidences of 
disrupted ER homeostasis. Our results therefore indicate that mutant huntingtin induces ER 
 103 
stress very early in the disease cascade of Hdh knock-in mice and very likely also in human 
disorder. 
ER stress has been detected as up-regulation of BiP, CHOP and Herpud1 mRNAs at 3 months 
of age. The rationale for such findings might be represented by the chaperone role of BiP and 
Herpud1, which are among the first genes to be induced upon ER stress. Furthermore, CHOP 
is a transcription factor whose expression is associated with an irreversible cellular death 
through apoptosis due to inability to overcome ER stress (Zinszner, 1998). Interestingly, at 1 
year of age the levels of both chaperones, BiP and Herpud1, continue to increase in knock-in 
mice, whereas the level of CHOP mRNA results down-regulated to the wild type level.  
A model for what we observed in knock-in mice may be that at 3 months of age cells try to 
overwhelm the problem of misfolded mutant huntingtin through the induction of ER 
chaperones; prolonged stress may then lead to apoptosis through the expression of death 
effectors as CHOP. Since CHOP transcription requires, among others, NF-Y, it is tempting to 
speculate that its down-regulation may be due to NF-Y sequestration into huntingtin 
aggregates, as shown by Yamanaka and colleagues (Yamanaka, 2008). Furthermore, this may 
provide an original explanation for an increased viability of MSNs-containing aggregates. 
Recently, Reijonen and colleagues have reported in PC6.3 cell line overexpressing N-terminal 
mutant huntingtin fragments clear evidences of ER stress. They observed upregulation of BiP 
and CHOP mRNAs, phosphorylation of JNK, cleavage of caspase 12 and 3 associated to 
pronounced cell death. Treatment with salubrinal, that inhibits ER stress, counteracted cell 
death and reduced protein aggregation caused by the mutant huntingtin fragment (Reijonen, 
2008). 
Moreover, we found the induction, at the transcriptional level, of BiP, CHOP, and Herpud1 as 
well as of Rrs1 and Lyric genes in striatal cell lines treated with tunicamycin, a chemical ER 
stress inducer. In these experimental conditions we observed a lower increase in mutant 
striatal cells with respect to wild type, possibly underlining a pre-existent stress provoked by 
the presence of mutant huntingtin. Indeed, mutant striatal cells show altered level of 
expression of both CHOP (induced) and Herpud1 (reduced), which may explain why these 
genes fail to reach a higher level of expression in these mutant cell lines upon ER stress. 
We believe that Rrs1 and Lyric may be helpful to understand the functional consequence of 
ER stress in HD  
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In Saccharomyces cerevisiae a defect in the secretory pathway causes the transcriptional 
repression of both ribosomal protein and rRNA genes. Rrs1 was first identified as an essential 
protein required for the secretory response (Tsuno, 2000). 
Since we have demonstrated that in mammalian cells Rrs1 mRNA expression is increased by 
ER stress, we hypothesize that Rrs1 might function as an ER stress sensor in HD, shuttling 
from the ER to the nucleolus to translate stress response into repression of ribosome synthesis. 
It will be important to assess whether in mammalian cells, as in yeast, Rrs1 participate in the 
transcriptional repression of ribosomal components induced by ER stress.  
Since Rrs1 depletion in Saccharomyces cerevisiae causes defects in the maturation of 25S 
rRNA and in the assembly and nuclear export of the 60S ribosomal subunit (Tsuno, 2000; 
Miyoshi, 2004), we also hypothesize that Rrs1 induction in HD may suggest a striatal 
impairment of ribosome biogenesis. 
Interestingly, previous reports are consistent with dysregulation of ribosome synthesis and 
alteration in the membrane compartments of HD patients (Wyttenbach, 2001; Trettel, 2000; 
Gauthier, 2004; Atwal, 2007), although further experiments are needed in human and mouse 
models as well. 
We are currently performing experiments to test these hypotheses by monitoring rDNA 
transcription and rRNA biogenesis in HD mouse models. 
These results show that mutant huntingtin activates cellular pathways linked to ER stress with 
mechanisms that are still unclear. It is likely that association of mutant huntingtin with cell 
membranes may influence calcium metabolism and activate signaling proteins in the ER 
(Rockabrand, 2007). This stress response may be more critical to the health of neuronal cell 
populations such as those in the striatum and the cortex. 
The data presented here suggest that compounds targeting ER stress may be considered in 
designing novel approaches for treatment of HD and possibly other polyQ diseases. 
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3.4 MATERIALS AND METHODS 
Plasmids 
Rrs1 in pcDNA3.0 (Invitrogen), encoding full length mouse Rrs1 (Riken clone # 5330427D04 
02.7.31) was digested out of the pBlueScript KS (+) plasmid with BamH1 and XhoI and 
subcloned into pcDNA3.0; HA-Lyric, encoding full length mouse N-terminal HA-tagged 
Lyric, was digested out of Fantom clone # 4931440A01 with EcoRI and XbaI and subcloned 
into pcDNA3.0-HA. 
Cell Culture 
STHdh striatal progenitor cell lines from wild-type (STHdhQ7/7) and homozygous 
(STHdhQ111/111) knock-in Hdh littermate mice embryos (E14 striatal primordial) were cultured 
at 33ºC in D-MEM (Dulbecco’s modified Eagle’s medium), 10% FBS (fetal bovine serum), 
100 U/ml penicillin, 100 g/ml streptomycin, 400 g/ml G418 for selection. 
The cells were immortalized with a Temperature Sensitive version of the SV40 Large T-
Antigen, which allows the cells to proliferate at the permissive temperature of 33ºC (Trettel et 
al., 2000). 
 
Hek 293T (human embryonic kidney) cells were cultured at 37ºC in D-MEM (Dulbecco’s 
modified Eagle’s medium), 10% FBS (fetal bovine serum), 100 U/ml penicillin, 100 g/ml 
streptomycin.  
Transfection: Calcium phosphate method 
Hek293T cells were transfected through the calcium phosphate method. 
Cells were plated in a 100mm culture dish the day before transfection so to reach about 60-
70% confluence at the time of transfection. 
A transfection mix composed by 0.25 mM CaCl2, 7 g plasmid DNA and H2O to a final 
volume of 500 l was added dropwise with bubbling to a tube containing 500 l HBS 2X (140 
mM NaCl, 1.5 mM Na2HPO4 • 2H2O, 50 mM HEPES pH 7.1). After 20 minutes incubation at 
RT the mixture was added to the cells. Cells were incubated overnight with the precipitates 
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and the medium was changed the day after. Cells were collected and assayed 40-48 hours after 
transfection. 
Treatment 
Tunicamycin: STHdhQ7/Q7 and STHdhQ111/Q111 striatal cells were treated with 1 µM 
tunicamycine for 3-6-12 hrs. 
Protein extraction and western blot 
Cells were washed in RT PBS 1X, then harvested in cold lysis buffers. 
Cells were lysed for 20 minutes rocking at 4°C and then centrifuged at 13,000 rpm for 15 
minutes at 4°C. 
Protein concentration was determined by Bradford assay using a calibration curve built with 
standard amounts of BSA (bovine serum albumin). 
Loading buffer was added and samples were boiled for 5 min. Proteins were separated by 
SDS-polyacrilamide gel electrophoresis (SDS-PAGE). 
Co-immunoprecipitation assays 
Cells were lysed with a Hepes pH 7.6 lysis buffer (10 mM Hepes pH 7.6, 1 mM EDTA, 150 
mM NaCl, 0.2% Triton-X 100), supplemented with protease inhibitor cocktail and 
phosphatase inhibitors (1mM sodium orthovanadate, 50mM NaF, 10 nM Okadaic Acid). After 
incubation 20 minutes rocking at 4°C samples were centrifuged 15 minutes at 4°C at 13,000 
rpm. Protein concentration was determined by Bradford. The same amount of total proteins (1-
2 mg) was used for each sample. The extracts were incubated with the immunoprecipitating 
antibody (2 g) for 2 hours at 4°C with rocking, then 25 l of Protein G Sepharose 50% slurry 
(Protein G Sepharose 4B, Amersham Biosciences) were added and incubated at 4°C rocking 
for 1 additional hour. Beads were pelleted at 800 rpm 2 minutes at 4°C and washed 3 times 
with the same lysis buffer, then dried out with a syringe. Samples were boiled in 20 l Sample 
Buffer 2X for 10 minutes before loading on SDS-polyacrylamide gel.  
Immunofluorescence 
Cells were seeded onto 13 mm coverslips and allowed to attach for 24 hours. After medium 
removal and washing in PBS cells were fixed in 4% paraformaldehyde for 15 minutes at RT. 
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After fixation, cells were rinsed in PBS and incubated 5 minutes with glycine 100 mM to 
quench autofluorescence. After rinsing in PBS cells were permeabilized with 0.2% Triton X-
100 for 4 minutes, washed again in PBS and incubated in BSA 0.2% for 1hour to block non 
specific sites before primary antibody incubation. 
Both primary and secondary antibodies were incubated in 0.2% BSA, 1% NGS. 
After primary antibody incubation, cells were washed 2 times in PBS and subjected to 
secondary antibody incubation. Nuclei were labeled with DAPI added during secondary 
antibody incubation. Cells were washed 2 times in PBS and mounted on slides using 
Vectashield mounting medium. 
Images were captured with a Leyca confocal microscope by using a 63X oil objective. 
Antibodies 
The following primary antibodies were used : Rabbit polyclonal anti-Rrs1 (FUN1; E. Fossale, 
MGH, Boston; WB dilution 1:500, IF dilution 1:30); mouse monoclonal anti-HA tag (kindly 
provided by Dr. L. Collavin, LNCIB, Ip 2 µg); Rabbit polyclonal anti-Lyric (Zymed Lab.,# 
40-6400, WB dilution 1:200, IF dilution 1:50); Anti-Calnexin (Chemicon, MAB3126, IF 
dilution 1:10), Mouse IgG (Sigma). 
The following HRP secondary antibodies were used: HRP conjugated goat anti-rabbit 
antibody (DAKO, WB dilution 1:2000). 
The following secondary antibodies were used for IF: Alexa-594 donkey anti-mouse (1:1000); 
Alexa-488 donkey anti rabbit (1:1000). 
Genotyping 
DNA was prepared from tail biopsy. CAG repeats were sized by PCR in GB buffer (66 mM 
Tris-HCl (pH 8.8), 16 mM (NH4)2SO4, 2 mM MgCl2, 0.7% b-Mercaptoethanol), 0.01 mg/ml 
BSA, 10% DMSO, 200µM dNTPs, 0.5µM primers with 0.4 U/µl RedTaq (Sigma). Cycling 
conditions were 90”@ 94°C, 35 X (30”@94°C, 30”@ 56/65°C, 90”@ 72°C), 10'@ 72°C. 
PCR products were resolved in 1% agarose gel. Primer sets were as follow: wild type 5'-
CCTGGAAAAGCTGATGAAGG-3', 5'-TGGACAGGGAACAGTGTTGC-3'; knock-in 5'-
ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC-3', 5'-GGCGGCTGAGGAAGCTGAG 
GA-3'. Genotyping of all animals was confirmed after dissection. 
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Wild-type and Hdh knock-in mouse brain dissections 
HdhQ111/111 and HhdQ7/7 knock-in mice expressing endogenous levels of huntingtin with 111 or 
7 glutamines have been described previously (White, 1997). 
Mice at 3 months or 1 year of age were euthanized by CO2 exposure following the CCM 
regulations and the brains were dissected into striatum, cortex and cerebellum, immediately 
frozen in liquid nitrogen, and stored at -80°C. 
RNA extraction and RT-qPCR 
Cells were washed in RT PBS 1X, then harvested in cold TRIZOL; mouse striata were 
homogenized in cold TRIZOL. RNA was extracted from six 3 months wild-type mice and six 
3 months heterozygous mice, and from six 1 year old wild-type mice and six 1 year old 
homozygous knock-in mice. 
Total RNA was isolated with TRIZOL reagent (Invitrogen/Life Technologies, Carlsbad, CA) 
according to manufacturer’s instructions, quantified spectrophotometrically at 260 nm, and 
analyzed by agarose gel electrophoresis. Total RNA used for quantitative RT–PCR assays was 
pretreated with DNase I using a DNA-free kit (Ambion Inc., Austin, TX, USA) and 
additionally purified over RNeasy Columns (Qiagen, Valencia, CA, USA). 
RT reactions were performed in 20 µl with 1 µg of DNase-treated total RNA, 1X reaction mix, 
and 1 µl of Reverse Transcriptase (Bio-rad, iSriptTM cDNA synthesis kit). Reaction conditions 
were 5 min at 25°C, 50 min at 42°C and 5 min at 85°C. Quantitative PCR reactions were 
performed with an iCycler iQ instrument (Bio-Rad Laboratories, Foster City, CA, USA), using 
the iQ Custom Syber Green Supermix (Bio-Rad). PCR reactions were performed in 25 µl 
reaction volumes containing 1 µl of cDNA, 250 nM of each primer and 1X reaction mix. Each 
reaction was performed in duplicate for the target and the normalizing gene (β-actin) in the 
same 96-well plate for all samples. Cycle parameters were 3 min at 95°C (10 s at 95°C, 20 s at 
58°C and 30 s at 72°C) for 40 cycles. To quantify the mRNA levels for each sample and 
primer set, a standard curve was generated with known dilutions of total cDNA. The relative 
value for each unknown sample was then calculated from its respective standard curve using 
linear regression analysis. To normalize the differences in the amount of total RNA added to 
each reaction, we used β-actin as endogenous control. The normalized expression value was 
then calculated by dividing the relative quantitation value of each sample and primer set by the 
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relative quantitation value of β-actin. Specificity of amplicon was determined by melt curve 
analysis and gel electrophoresis. 
 Primers were designed for each gene using Beacon Design 5.0 software (Premier Biosoft 
International, Palo Alto, CA, USA). Specific forward and reverse primers (TIB MOLBIOL, 
Genova, Italy) were as follows: murine Rrs1 (GenBank accession no. NM_021511), 5'-
GCAAGTATTGTAAATGGATGCAG-3', 5'-TCTCAAGCACACTCCATATTG-3'; murine 
Lyric (GenBank accession no. NM_026002), 5'-CTCTCGGGCTGCTCCTGCTCTTC-3', 5'-G 
GCGGGCTCCTTCGCTTCTTGCG-3'; murine β-actin (GenBank accession no. NM_007393), 
5'-TGAAATAAGTGGTTACAGGAAGTC-3', 5'-GCAGTACATAATTTACACAGAAGC-3'; 
murine CHOP (GenBank accession no. NM_007837), 5'-GAGCTGGAAGCCTGGTATGA 
G-3', 5'-TGTGCGTGTGACCTCTGTTGG-3'; murine BiP (GenBank accession no. 
NM_022310), 5'-GAGCGTCTGATTGGCGATGC-3', 5'-TTCCAAGTGCGTCCGATGAG 
G-3'; murine Herpud1 (GenBank accession no. NM_022331), 5'-GGAGCCAATCAGAACTT 
GCG-3', 5'- ATAGGTCCAATCCAACCAGTCTCG-3'. 
Statistical analyses 
Statistical analyses were Student’s t-test, choosing P<0.05 as significant. Weighted means 
were calculated for data produced in replica experiments. Calculated means and standard 
deviations were plotted using the graph tool of Microsoft Excel. 
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CONCLUSIONS 
The work performed in this thesis was aimed to identify toxic molecular mechanisms in the 
HD pathogenic cascade using two complementary lines of investigations.  
 
In the first part of this work we have hypothesized that the peptidyl-prolyl isomerase Pin1 may 
be involved in HD pathogenic mechanisms. This enzyme has been already implicated in other 
neurodegenerative disorders in modulating fundamental properties of the disease proteins. In 
this context, Pin 1 could play a pivotal role also in HD and be considered as a potential drug 
target. In support to our hypothesis we have demonstrated that Pin1, when overexpressed in 
cell culture, reduces mutant huntingtin aggregate formation. Moreover, we found that Pin1 
decreases huntingtin half-life by inducing proteasome pathway activity.  The involvement of 
the proteasome is of particular interest being its dysregulation already linked to HD, as well as 
to other neurodegenerative disorders.  
Several hypotheses may be formulated on the functional consequences of the modulation of 
huntingtin aggregation by Pin1. 
In AD, Pin1 binds the phosphorylated Thr-231-Pro motif of tau and, by enhancing its 
dephosphorylation, restores tau function and reduces the formation of neurofibrillary tangles 
(Lu, 1999). Thus, in this context, Pin1 exerts a protective role. Interestingly, analysis of Pin1 
activity in AD brain demonstrated that oxidation of Pin1 leads to loss of activity. The in vivo 
oxidative modification of Pin1 as found by proteomics in AD hippocampus suggests that 
oxidative modification may be related to the loss of Pin1 activity that could be crucial in AD 
neurofibrillary pathology.  
In PD, in contrast to AD, Pin1 inhibits the degradation of -synuclein and enhances the 
formation of the Lewy Bodies (LB) cytoplasmic inclusions (Kesavapany, 2007). The question 
of whether intracellular inclusions protect or are cytotoxic for neurons is still controversial. It 
is therefore difficult to conclude if Pin1 protects or enhances cell death in the dopaminergic 
neurons of PD brains.  
In HD we do not currently have sufficient data to support either a protective or a toxic role for 
Pin1. Several scenarios may be played out including a changing role according to the 
pathogenic stage.  
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It will be interesting to assess whether Pin1 is a component of HD inclusions in postmortem 
brains and/or it is downregulated. 
These data may have profound effects on strategies for therapeutic interventions. 
Interestingly, we also found that Pin1 may modulate transcriptional dysregulation induced by 
mutant huntingtin, further supporting a role for this enzyme in the HD neurodegenerative 
process. The generation of a double HdhQ111KI/Pin1KO mouse line and ongoing studies aimed 
to elucidate the role of Pin1 in modulating HD phenotypes in vivo will provide interesting 
clues.  
 
In the second part of this thesis we focused our attention on Rrs1, a gene whose expression 
was previously found upregulated in HdhQ111 KI mice, a pre-symptomatic model of HD. Up to 
now, Rrs1 protein has been studied only in yeast where it participates in ribosomes biogenesis. 
We have considered that knowing Rrs1 function in mammalian cells could provide insight into 
the early mechanisms of the disease process. In fact, we have described for the first time Rrs1 
protein in mammalian cells, where it localizes both in the nucleoli and in the ER. In addition, 
we have shown that mRNA level of both Rrs1 and its partner Lyric are induced upon ER 
stress in striatal cell lines. Interestingly, we found that ER stress is a new early phenotype of 
HdhQ111 knock-in mice. In conclusion, studying Rrs1 we have identified a new pathway that is 
altered in the early phase of the disease cascade and that surely deserve future investigations. 
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APPENDIX 2: ISOLATION OF PEPTIDE APTAMERS TO TARGET MUTANT 
HUNTINGTIN-INDUCED ABNORMAL PHENOTYPES 
 
During the first year of my PhD course, I had been involved in a different project, than those 
presented in the previous chapters. 
In particular, the project I had worked on was focusing on the identification of small 
molecules, peptides, able to interact with mutant huntingtin.  
The strategy of using peptide aptamers that selectively interact with target proteins interfering 
with the protein functions has been widely validated (Colas, 1996; Guida, 2008). The isolation 
of peptide aptamers that bind mutant huntingtin may represent therefore a valuable approach 
to hamper inappropriate interactions and to dissect HD pathogenic pathways. In addition, 
peptide aptamers provide a platform for the design of pharmacologically active drugs that may 
specifically slow the disease progression.  
We report here the expression of a combinatorial library of constrained 16-residues peptides 
displayed by the active site loop of E. coli thioredoxin and the use of a yeast two-hybrid 
system to select those that might be able to revert mutant huntingtin-induced abnormal 
phenotypes. 
Work performed and Results 
Making and testing the baits 
To isolate peptides aptamers that bind huntingtin we first generated bait clones expressing the 
N-terminal region of huntingtin, with 20 or 62 glutamines, as fusion proteins in pLexA vector 
(pLexA-HD1-550Q20 and pLexA-HD1-550Q62). The baits were transformed into the EGY48 
MAT-alpha yeast strain containing the lacZ reporter plasmid (pSH18-34) to generate the bait 
strains EGY48Nt-wt (EGY48/pSH18-34/pLexA-HD1-550Q20) and EGY48Nt-mut 
(EGY48/pSH18-34/pLexA-HD1-550Q60). The accurate expression of the fusion proteins in the 
bait strains was assessed by western blot (Fig. 1). Potential autoactivation of the baits was 
tested and excluded by the lack of expression of the reporter genes Leu2 and LacZ.  
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Figure 1:  Bait expression test. EGY48/pSH18-34 was transformed with pLexA, pLexA-HD1-550Q20, pLexA-HD1-
550Q60 or pLexA-Rrs1 (control). 72 hours after transfection a single colony was cultured ON in liquid 
medium and the day after cells were lysed for protein extraction. Blot probed for LexA DBD (α-LexA 
dilution 1:1000). 
Library transformation 
The bait strains EGY48Nt-wt/mut were subsequently transformed with a combinatorial 
peptide library, kindly provided by Prof. G. Del Sal. The library encodes E. coli thioredoxin 
(TrxA) with about 109 random 16-mer peptides in its active site (Guida, 2008). For each bait a 
total of ~ 7 x 106 colonies were plated into selective media and screened for LacZ and Leu2 
expression. As result of this primary screening we have identified 26 positive colonies.  
To verify the specificity of the interaction we performed a secondary screening in yeast. 
Positive prey plasmids were recovered and retransformed into their respective bait strains. 
Clones positive to the secondary screening were recovered and sequenced; seven peptides 
were identified. 
Bioinformatics analysis of the identified peptide aptamers shows that they have no significant 
similarity to any known protein, but it is worth noting that they share a positively-charged 
region (Fig. 2) which could represent a common motif, and so a common way of interaction. 
The repertoire of binding affinities to mutant and wild-type huntingtin for the various peptides 
is under investigation. Excitingly preliminary data in yeast suggest that some of the peptides 
specifically bind mutant huntingtin. Modelling studies of the peptides could reveal interesting 
insights on this direction. 
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Figure 2:  Multiple sequence alignment of the 7 identified peptides. Colours highlight high homology residues. 
Peptide analysis in mammalian cells 
Positive peptides, constrained in the thioredoxin scaffold, were sub-cloned into pcDNA3.0 
vector and their expression in mammalian cells was assessed by western analysis. 
In order to evaluate the ability of the selected peptides to revert the abnormal phenotypes in 
STHdh mutant striatal cells we first focused our attention on the two peptides which seemed to 
show specificity in mutant huntingtin binding, and on CBP measurement as single cell assay. 
No rescue of CBP mutant phenotype was observed for both of them. Unfortunately, our 
transfection efficiency was not sufficient for assessing cell viability and BDNF levels. 
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ABBREVIATIONS 
 
3-NP   3-nitropropionic acid 
aa   amino acid 
AD   Alzheimer’s disease 
ALS   amyotrophic lateral sclerosis 
APP  amyloid precursor protein 
AVP  arginine vasopressin 
BDNF  brain-derived neurotrophic factor 
CA150  co-activator 150 
CAG   cytosine adenine guanine 
CBP   (c-AMP-response-element-binding protein) binding protein 
Cdk5  cyclin-dependent kinase 5 
CHX  cycloheximide 
CHIP  carboxy terminus of Hsp70p-interacting protein 
CHOP  C/EBP homologous protein 
CNS   central nervous system 
CNTF   ciliary neurotrophic factor 
CtBP   C-terminal-binding protein 
DMSO  di-methyl sulfoxide 
DRPLA  dentatorubralpallidoluysian atrophy 
ER  endoplasmic reticulum 
ERAD  ER activated degradation 
FL  full-length 
GABA  gamma-aminobutyric acid 
GFP  green fluorescent protein 
GPe   external segment of the globus pallidus 
GPi   internal segment of the globus pallidus 
GST  glutathione-S-transferase  
TGase  transglutaminase 
HAP1   huntingtin-associated protein 1 
HD   Huntington’s disease 
Herpud1 homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like 
domain member 1 
HIP1  huntingtin-interacting protein-1 
HIP-14  huntingtin-interacting protein-14 
Hippi   Hip-1 protein interactor 
Hsp40   heat shock protein 40 kDa 
Hsp70   heat shock protein 70 kDa 
Hsp90   heat shock protein 90 kDa 
htt  huntingtin 
IF  immunofluorescence 
IT15  interesting transcript 15 
KI  Knock-in 
KO  Knock-out 
MSNs   medium sized spiny neurons 
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N-CoR  nuclear receptor co-repressor 
NGF   nerve growth factor 
NII  neuronal intranuclear inclusion 
NMDA  N-metyl-D-aspartate 
P/CAF  p300/CBP associated factor 
PD   Parkinson’s disease 
Pin1  protein interacting with NIMA (never in mitosis A) 1 
PP2A  protein phosphatase 2 A 
PPases  protein phosphatases 
PPIases peptidyl-prolyl isomerases 
PSD-95  postsynaptic density-95 
Q   glutamine 
REST   RE1-silencing transcription factor 
RF  RISC-Free siRNA 
RISC  RNA-induced silencing complex 
RRB  ribosome and rRNA biosynthesis regulon 
Rrs1  regulator of ribosome synthesis 
ROS  reactive oxygen specie 
RT  Room Temperatura 
SBMA  spinobulbar muscular atrophy 
SCA   spinocerebellar ataxia 
SGK   serum- and glucocorticoid-induced kinase 
siRNA  small interference RNA 
Sp1   specificity protein 1 
STN   subthalamic nucleus 
TAFII130  TATA-binding protein (TBP)-associated factor 
TBP   TATA-box binding protein 
UBE3A ubiquitin protein ligase E3A 
UPP   ubiquitin-proteasome pathway 
UPS  ubiquitin-proteasome system 
Wt   wild-type 
WB  western blot 
YAC   yeast artificial chromosome 
YFP  yellow fluorescent protein 
 
